Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hematology›Condition·Updated Jul 11, 2026·v1

Venous Thromboembolism

Venous thromboembolism is a common and potentially fatal condition requiring prompt diagnosis and anticoagulation. DOACs have replaced warfarin for most indications, with risk-stratified duration based on provoked status, DASH score, and bleeding risk. Extended therapy with reduced-dose DOACs balances efficacy and safety. Special populations (cancer, pregnancy, pediatrics, antiphospholipid syndrome) require tailored approaches.

High Evidence522 references·2,218 words·9 min read·v1
Venous ThromboembolismDeep Vein ThrombosisPulmonary EmbolismAnticoagulationDOACThrombophiliaCancer-Associated ThrombosisPost-Thrombotic SyndromeHematology

Quick Reference

RxDrug of choiceApixaban 10 mg BID x7d then 5 mg BID (or rivaroxaban 15 mg BID x21d then 20 mg daily) for acute VTE.
AltAlternativesLMWH (enoxaparin 1 mg/kg BID or 1.5 mg/kg daily), warfarin (INR 2-3), edoxaban 60 mg daily after 5 days of LMWH.
⊘AvoidDOACs in antiphospholipid syndrome (triple positive), severe renal impairment (CrCl <15 mL/min for most DOACs), severe hepatic impairment (Child-Pugh B/C), pregnancy (DOACs).
DxTest of choiceCompression ultrasound for DVT; CTPA for PE; D-dimer (high-sensitivity) for exclusion in low/moderate pretest probability.
ScKey scoreWells score for pretest probability; sPESI for PE severity; Khorana score for cancer-associated VTE risk.
→When to referRecurrent VTE on adequate therapy, unusual site thrombosis, suspected thrombophilia or antiphospholipid syndrome, cancer-associated VTE requiring multidisciplinary management.
Immediate DOAC anticoagulation, risk-stratified duration based on provoked/unprovoked status, and extended therapy with reduced-dose DOAC for unprovoked VTE or active cancer.
Venous thromboembolism (VTE) is a disease entity comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), a leading cause of cardiovascular morbidity and mortality worldwide. Proper classification, risk stratification, and evidence-based management are essential to reduce recurrence, complications, and death. This summary condenses key clinical facts, drug doses, thresholds, and citations for bedside reference.

Overview and Recommendations

Background

  • •Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of cardiovascular death worldwide, with an annual incidence of 1-2 per 1000 individuals and a 5-year recurrence approaching 20%, making it a major contributor to inpatient morbidity and long-term disability.
  • •The pathophysiology is a modern elaboration of Virchow's triad: unopposed thrombin generation driven by endothelial injury, stasis, and hypercoagulability, with thromboinflammatory contributions from neutrophil extracellular traps ( ), procoagulant platelets, and clonal hematopoiesis (e.g., mutations), particularly in older adults and cancer patients.
  • •The provoked-unprovoked axis is the primary determinant of recurrence risk: a first unprovoked proximal DVT or PE carries a 10% annual recurrence rate off anticoagulation, whereas a major transient risk factor (surgery, trauma) reduces recurrence to <5%, driving different durations of therapy.
  • •Four landmark trials established as the standard of care: (apixaban), (rivaroxaban), (edoxaban), and (dabigatran), collectively demonstrating noninferior efficacy and superior safety compared to .
  • •Cancer-associated VTE accounts for ~20% of all VTE and carries the highest recurrence and mortality; (apixaban vs dalteparin) and (rivaroxaban vs dalteparin) now support DOACs as first-line in most cancer patients, with caution in GI/genitourinary tumors.
  • •The 2026 AHA/ACC PE classification replaced 'massive/submassive' with hemodynamic and RV-based risk categories (high-, intermediate-, low-risk), directly guiding triage and reperfusion decisions.

Evaluation

  • •Suspect VTE in any patient with unilateral leg swelling/pain (DVT) or acute dyspnea, pleuritic chest pain, hemoptysis, or syncope (PE); risk factors include recent surgery, cancer, immobilization, pregnancy, or prior VTE.
  • •Assess pretest probability using a validated score: for PE, or ; for DVT, , a low or moderate probability allows D-dimer as first test.
  • •Order a high-sensitivity D-dimer (ELISA method) when probability is low or moderate; a negative D-dimer (<500 ng/mL) safely excludes VTE without imaging (3-month failure rate <1%), use age-adjusted thresholds (age × 0.1 mg/L for >50 years) to improve specificity.
  • •For low-probability PE with D-dimer <1000 ng/mL (per strategy), the failure rate is 0.0%, allowing avoidance of imaging in ~30% of patients.
  • •If D-dimer is positive or probability is high, proceed to imaging: (CUS) for DVT (proximal veins); (CTPA) for PE, if CTPA contraindicated (renal impairment, contrast allergy, pregnancy).
  • •In pregnancy, use the pregnancy-adapted : rule out PE if no YEARS criteria and D-dimer <1000 ng/mL, or ≥1 criterion and D-dimer <500 ng/mL, avoiding CTPA in 39% of women.
  • •Examine for signs of severity in PE: tachycardia, hypotension, hypoxia, jugular venous distension, RV heave, loud P2, these indicate high-risk PE requiring immediate reperfusion.
  • •Order troponin and /NT-proBNP in PE to identify myocardial injury and RV strain; is essential if intermediate-risk PE to assess RV size/function.
  • •Consider thrombophilia testing only in select patients: age <50, unprovoked VTE, recurrent VTE, family history, unusual site thrombosis, or suspected , test for factor V Leiden, prothrombin G20210A, antithrombin, protein C/S, and lupus anticoagulant.
  • •In cancer patients with VTE, assess for underlying with JAK2 V617F mutation if splanchnic vein thrombosis or unexplained thrombocytosis; stratifies primary VTE risk.
  • •Differential diagnosis: cellulitis (DVT), Baker's cyst rupture, musculoskeletal pain, pneumonia, pericarditis, myocardial infarction, aortic dissection (PE mimics).
  • •In children, use the rule: safe exclusion of PE with false-negative rate 0.1% (sensitivity 99.6%), consider as a prime risk factor.

Management

  • •Initiate anticoagulation immediately after VTE is diagnosed (or while testing is pending if high probability), for most patients, start a without parenteral heparin: 10 mg twice daily for 7 days then 5 mg twice daily, or 15 mg twice daily for 21 days then 20 mg once daily with food.
  • •In hemodynamically unstable high-risk PE (systolic BP <90 mmHg), give with alteplase 100 mg IV over 2 hours if no major contraindication; or surgical embolectomy is an alternative.
  • •For intermediate-risk PE (normotensive with RV strain), start anticoagulation and monitor closely; reserve thrombolysis for clinical deterioration, low-dose alteplase 20 mg via ultrasound-assisted catheter reduced thrombus burden but with increased bleeding risk (not proven to reduce mortality).
  • •In cancer-associated VTE, apixaban (same dosing) or rivaroxaban are first-line; for GI or genitourinary tumors with high bleeding risk, consider (e.g., 1 mg/kg twice daily) as initial and extended therapy.
  • •For patients requiring immediate reversal (major bleeding on DOACs), use for factor Xa inhibitors (apixaban, rivaroxaban) or for dabigatran; for heparin, protamine 1 mg per 100 U.
  • •After 3 months of anticoagulation, decide on extended therapy: for a first provoked VTE (major transient risk factor), stop after 3 months; for unprovoked VTE, consider indefinite therapy if bleeding risk is low, use to individualize.
  • •Extended therapy options: reduced-dose DOACs are preferred, 2.5 mg twice daily or 10 mg once daily, proven noninferior to full dose with less major bleeding ( trial).
  • •For cancer-associated VTE requiring extended therapy, reduced-dose apixaban 2.5 mg twice daily after 6 months is noninferior to full dose with fewer clinically relevant bleeds ( trial).
  • •In antiphospholipid syndrome (especially triple positive), avoid DOACs, use targeting INR 2-3; for myeloproliferative neoplasms, combine anticoagulation with cytoreduction (hydroxyurea for PV/ET).
  • •In pregnancy, use LMWH (e.g., enoxaparin 1 mg/kg twice daily or 1.5 mg/kg daily) throughout pregnancy and for ≥6 weeks postpartum; DOACs are contraindicated.
  • •In children, use weight-adjusted or (if age ≥2), per EINSTEIN-Jr and DIVERSITY trials.
  • •Monitor renal function (CrCl) and hepatic function before and during therapy; adjust DOAC doses for CrCl 15-29 mL/min; avoid DOACs in Child-Pugh B/C.
  • •Do not use alone for secondary prevention in unprovoked VTE, DOACs are significantly more effective (EINSTEIN CHOICE).
  • •Do not routinely use , consider only if anticoagulation is contraindicated and acute proximal DVT or PE.
  • •After DVT, prescribe graduated compression stockings (30-40 mmHg) for symptomatic leg swelling but not for primary prevention of post-thrombotic syndrome; encourage early mobilization.
  • •Refer to a thrombosis clinic or hematologist for recurrent VTE, VTE in unusual sites (cerebral, splanchnic), antiphospholipid syndrome, or when thrombophilia testing results will alter management.

Board Review — High Yield

  • •Provoked vs. Unprovoked, The distinction drives recurrence risk: provoked (transient risk factor) → stop at 3 months; unprovoked → consider indefinite therapy.
  • •DASH score, Used to guide anticoagulation duration after unprovoked VTE: score ≤1 (low recurrence) may stop; ≥3 (high recurrence) should continue.
  • •DOAC superiority, Apixaban and rivaroxaban are noninferior to warfarin with 50-70% less major bleeding; no routine monitoring required.
  • •Cancer-associated VTE, Apixaban is first-line (Caravaggio); rivaroxaban effective but higher GI bleeding; reduced-dose after 6 months is safe.
  • •Antiphospholipid syndrome, DOACs are contraindicated (especially triple positive); warfarin INR 2-3 remains standard.
  • •Massive PE, Immediate systemic thrombolysis (alteplase 100 mg) if no contraindication; hypotension is the trigger.
  • •RENOVE/API-CAT trials, Reduced-dose DOACs (apixaban 2.5 mg BID) noninferior to full dose for extended therapy with less bleeding.
  • •Pregnancy-adapted YEARS, Avoids CTPA in 39% of pregnant women; LMWH is treatment of choice throughout pregnancy and postpartum.
  • •D-dimer age adjustment, Use age x 0.1 mg/L for patients >50 years to improve specificity; a negative result safely excludes VTE.
  • •Khorana score, Validated for primary prophylaxis in ambulatory cancer patients; score ≥2 warrants consideration of apixaban 2.5 mg BID.

Deep Dive — Evidence Details

References

  1. [1]

    Barnes GD, Ageno W, Castellucci LA et al.. “Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36796485 ↗

    L1GUIDELINECited in: 1. Definition, Classification & Nomenclature
  2. [2]

    Eerenberg ES, Middeldorp S, Levi M et al.. “Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26179293 ↗

    L2RCTCited in: 1. Definition, Classification & Nomenclature
  3. [3]

    Guman NAM, Mulder FI, Ferwerda B et al.. “Polygenic risk scores for prediction of cancer-associated venous thromboembolism in the UK Biobank cohort study.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37481074 ↗

    L2COHORTCited in: 1. Definition, Classification & Nomenclature
  4. [4]

    Branchford BR, Mourani P, Bajaj L et al.. “Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation.” Haematologica (2011). PMID: 22133768 ↗

    L3CASE_CONTROLCited in: 1. Definition, Classification & Nomenclature, 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 6. Staging, Risk Stratification & Prognostic Scoring, 11. Complications, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  5. [5]

    Blondon M, Harrington LB, Righini M et al.. “Racial and ethnic differences in the risk of postpartum venous thromboembolism: a population-based, case-control study.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 25279442 ↗

    L3CASE_CONTROLCited in: 1. Definition, Classification & Nomenclature
  6. [6]

    Cordua S, Kjaer L, Skov V et al.. “Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population.” Blood (2019). PMID: 31217187 ↗

    L4OTHERCited in: 1. Definition, Classification & Nomenclature
  7. [7]

    Creager MA, Barnes GD, Giri J et al.. “2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2026). PMID: 41712898 ↗

    L1GUIDELINECited in: 1. Definition, Classification & Nomenclature
  8. [8]

    Creager MA, Barnes GD, Giri J et al.. “2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2026). PMID: 41712677 ↗

    L1GUIDELINECited in: 1. Definition, Classification & Nomenclature
  9. [9]

    Manning JE, Arachchillage DJ. “Dilemmas in the diagnosis and management of antiphospholipid syndrome.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38705387 ↗

    L5CASE_REPORTCited in: 1. Definition, Classification & Nomenclature, 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  10. [10]

    Chiang CH, Song J, Chang YC et al.. “Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation.” Blood advances (2025). PMID: 39908569 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature
  11. [11]

    Kumar R, Stanek J, Creary S et al.. “Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.” Blood advances (2018). PMID: 29431623 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature
  12. [12]

    Hendriksen JM, Geersing GJ, Moons KG et al.. “Diagnostic and prognostic prediction models.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23809117 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification & Nomenclature, 6. Staging, Risk Stratification & Prognostic Scoring
  13. [13]

    Kaweme NM, Buttress SMN, Nguweneza A et al.. “Burden and outcomes of cardiovascular and pulmonary complications in adolescents and adults with sickle cell disease: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 41673762 ↗

    L2SR_OBSCited in: 1. Definition, Classification & Nomenclature
  14. [14]

    Zhang Q, Yao Y, Wei Y et al.. “Independent and Joint Associations of Circadian Rhythm Patterns and Physical Activity Levels With Venous Thromboembolism: A Large-Scale Cohort Study Using Accelerometry Measurements.” Journal of physical activity & health (2026). PMID: 41569854 ↗

    L2COHORTCited in: 1. Definition, Classification & Nomenclature
  15. [15]

    Yang YJ, Yan HB, Liu WT et al.. “Application of machine learning to predict the occurrence of venous thromboembolism in patients hospitalized for coronary artery disease: a single-center retrospective study.” Frontiers in cardiovascular medicine (2025). PMID: 41393263 ↗

    L2COHORTCited in: 1. Definition, Classification & Nomenclature
  16. [16]

    Mian UU, Hameed A, Azeem T et al.. “The Endoscopic Versus Open Approach for Anterior Skull Base Tumors: A Systematic Review of Comparative Outcomes and a Framework for Surgical Selection.” Neurology research international (2025). PMID: 41281588 ↗

    L2SR_OBSCited in: 1. Definition, Classification & Nomenclature
  17. [17]

    Verhamme P, Yi BA, Segers A et al.. “Abelacimab for Prevention of Venous Thromboembolism.” The New England journal of medicine (2021). PMID: 34297496 ↗

    L1RCTCited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  18. [18]

    Austin H, Key NS, Benson JM et al.. “Sickle cell trait and the risk of venous thromboembolism among blacks.” Blood (2007). PMID: 17409269 ↗

    L3TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism
  19. [19]

    Dentali F, Squizzato A, Brivio L et al.. “JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.” Blood (2009). PMID: 19273837 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism
  20. [20]

    Watson HG, Baglin TP. “Guidelines on travel-related venous thrombosis.” British journal of haematology (2010). PMID: 21083651 ↗

    L1GUIDELINECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  21. [21]

    Carlin S, Cuker A, Gatt A et al.. “Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38823454 ↗

    L1GUIDELINECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  22. [22]

    Brandão LR, Tartakovsky I, Albisetti M et al.. “Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.” Blood advances (2022). PMID: 36150047 ↗

    L2TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  23. [23]

    Marchiori A, Mosena L, Prins MH et al.. “The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.” Haematologica (2007). PMID: 17650440 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management
  24. [24]

    van Vlijmen EF, Wiewel-Verschueren S, Monster TB et al.. “Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 27121914 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism
  25. [25]

    El-Galaly TC, Severinsen MT, Overvad K et al.. “Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case-cohort study.” British journal of haematology (2012). PMID: 23150947 ↗

    L3COHORTCited in: 2. Pathophysiology & Mechanism
  26. [26]

    Englisch C, Vostatek R, Schramm T et al.. “Association of clonal haematopoiesis with recurrent venous thromboembolism: A case-control study.” British journal of haematology (2024). PMID: 39497597 ↗

    L3CASE_CONTROLCited in: 2. Pathophysiology & Mechanism
  27. [27]

    Zon RL, Sekar A, Clapham K et al.. “JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism.” Blood (2024). PMID: 39102652 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism
  28. [28]

    Kaiser R, Dewender R, Mulkers M et al.. “Procoagulant platelet activation promotes venous thrombosis.” Blood (2024). PMID: 39440970 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  29. [29]

    Kaiser R, Anjum A, Nicolai L. “Platelet heterogeneity in disease: the many and the diverse?” Blood (2025). PMID: 40906924 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  30. [30]

    Dahlbäck B. “Advances in understanding pathogenic mechanisms of thrombophilic disorders.” Blood (2008). PMID: 18574041 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  31. [31]

    Warkentin TE, Anderson JA. “How I treat patients with a history of heparin-induced thrombocytopenia.” Blood (2016). PMID: 27114458 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment
  32. [32]

    Vedantham S, Sista AK. “How I use catheter-directed interventional therapy to treat patients with venous thromboembolism.” Blood (2018). PMID: 29295847 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment
  33. [33]

    ten Kate MK, Mulder R, Platteel M et al.. “Identification of a novel PROS1 c.1113T-->GG frameshift mutation in a family with mixed type I/type III protein S deficiency.” Haematologica (2006). PMID: 16885060 ↗

    L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism
  34. [34]

    Falanga A, Marchetti M. “Venous thromboembolism in the hematologic malignancies.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19752334 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  35. [35]

    Ahlbrecht J, Dickmann B, Ay C et al.. “Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23008313 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism
  36. [36]

    Kasthuri RS, Taubman MB, Mackman N. “Role of tissue factor in cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19738116 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  37. [37]

    Kroone C, Tieken C, Kocatürk B et al.. “Tumor-expressed factor VII is associated with survival and regulates tumor progression in breast cancer.” Blood advances (2023). PMID: 36920782 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  38. [38]

    Lee EJ, Dykas DJ, Leavitt AD et al.. “Whole-exome sequencing in evaluation of patients with venous thromboembolism.” Blood advances (2017). PMID: 29296762 ↗

    L4OTHERCited in: 2. Pathophysiology & Mechanism
  39. [39]

    Kendrick NC, Harvey GJ, Castro SA et al.. “Neutrophil cathepsin G potentiates biased signaling through protease-activated receptor 4.” Blood advances (2026). PMID: 41370205 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  40. [40]

    Todorovski A, Wang TF, Carrier M et al.. “CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease.” Blood advances (2025). PMID: 39561373 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  41. [41]

    Obiorah IE, Patel BA, Groarke EM et al.. “Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.” Blood advances (2021). PMID: 34427584 ↗

    L4OTHERCited in: 2. Pathophysiology & Mechanism
  42. [42]

    Noone DG, Iijima K, Parekh R. “Idiopathic nephrotic syndrome in children.” Lancet (London, England) (2018). PMID: 29910038 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 11. Complications
  43. [43]

    Al-Samkari H, Kasthuri RS, Parambil JG et al.. “An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.” Haematologica (2021). PMID: 32675221 ↗

    L4OTHERCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  44. [44]

    Conran N, De Paula EV. “Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.” Haematologica (2020). PMID: 33054078 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  45. [45]

    Gran OV, Smith EN, Brækkan SK et al.. “Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism.” Haematologica (2016). PMID: 27479824 ↗

    L3OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  46. [46]

    Kim HJ, Seo JY, Lee KO et al.. “Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population.” Haematologica (2013). PMID: 24162787 ↗

    L3OTHERCited in: 2. Pathophysiology & Mechanism
  47. [47]

    Navarro S, Medina P, Mira Y et al.. “Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation.” Haematologica (2008). PMID: 18403391 ↗

    L3OTHERCited in: 2. Pathophysiology & Mechanism
  48. [48]

    Hald EM, Brækkan SK, Mathiesen EB et al.. “High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study.” Haematologica (2011). PMID: 21508123 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism
  49. [49]

    Steensma DP. “Clonal haemopoiesis and venous thromboembolism risk.” British journal of haematology (2024). PMID: 39543860 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  50. [50]

    Preston RJS, O'Sullivan JM, O'Donnell JS. “Advances in understanding the molecular mechanisms of venous thrombosis.” British journal of haematology (2019). PMID: 30906986 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 12. Prognosis & Natural History
  51. [51]

    Wilson S, Ellsworth P, Key NS. “Pregnancy in sickle cell trait: what we do and don't know.” British journal of haematology (2020). PMID: 32064587 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 13. Special Populations & Pregnancy
  52. [52]

    O'Neill C, O'Connell C. “Idiopathic erythrocytosis: A diagnostic and management challenge with emerging areas for exploration.” British journal of haematology (2024). PMID: 38262687 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 11. Complications, 12. Prognosis & Natural History
  53. [53]

    Swan D, Rocci A, Bradbury C et al.. “Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.” British journal of haematology (2018). PMID: 30450656 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 12. Prognosis & Natural History
  54. [54]

    Swan D, Turner R, Grove EL et al.. “Direct oral anticoagulant failure in patients with venous thromboembolism-why and what next?” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40199444 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  55. [55]

    Najem MY, Couturaud F, Lemarié CA. “Cytokine and chemokine regulation of venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32020753 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  56. [56]

    Baglin T. “What happens after venous thromboembolism?” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19630818 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  57. [57]

    Saadatagah S, Kim RB, Sukumar S et al.. “Clonal hematopoiesis of indeterminate potential and incidence of venous thromboembolism in older adults.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40252845 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment
  58. [58]

    Jenkins EO, Schiff D, Mackman N et al.. “Venous thromboembolism in malignant gliomas.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19912518 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 6. Staging, Risk Stratification & Prognostic Scoring
  59. [59]

    Conway EM, Pryzdial ELG. “Is the COVID-19 thrombotic catastrophe complement-connected?” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32762081 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 7. Acute & Emergency Management
  60. [60]

    Reikvam H, Tiu RV. “Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.” Leukemia (2011). PMID: 22076463 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  61. [61]

    de Sousa Bernardes L, de Oliveira Woehl L, de Oliveira JG et al.. “Assessment of venous thromboembolism in adult-type diffuse gliomas at a quaternary neuro-oncology center: a retrospective cross-sectional study and systematic review.” Neurosurgical review (2026). PMID: 42032381 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism
  62. [62]

    Prouse T, Majumder R, Majumder S. “High Intratumoral PROS1 Expression Correlates with Improved Survival and Is Associated with Suppressed Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma.” International journal of molecular sciences (2026). PMID: 41977152 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism
  63. [63]

    Navarro SM, Thompson RJ, Spears GM et al.. “Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study.” Shock (Augusta, Ga.) (2026). PMID: 41886536 ↗

    L2COHORTCited in: 2. Pathophysiology & Mechanism
  64. [64]

    Kumar R, Rodriguez V, Cohen C et al.. “Nonextremity thrombosis sequelae in children: screening, diagnosis, and management.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41833694 ↗

    L5CASE_REPORTCited in: 2. Pathophysiology & Mechanism
  65. [65]

    Chiara E, Bagni G, Raho A et al.. “Mechanisms, clinical manifestations and management of cardiovascular diseases in ANCA-associated vasculitis.” Rheumatology (Oxford, England) (2026). PMID: 42391608 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  66. [66]

    Acquasaliente L, Pierangelini A, Uliana F et al.. “The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na+ Binding and Preferentially Hinders the Protease Anticoagulant Functions.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42372952 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  67. [67]

    Mayger K, Orlando C, Hunt BJ. “Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42362031 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  68. [68]

    Yin J, Zhu E, Zheng X et al.. “Immune drivers of venous thrombosis: orchestrating initiation, formation, and resolution within the hypoxic microenvironment.” Frontiers in immunology (2026). PMID: 42358987 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, History and Evolution of Treatment
  69. [69]

    Brandão LR, Driscoll J, Newburger JW et al.. “Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.” The Lancet. Haematology (2026). PMID: 42392108 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  70. [70]

    O'Brien SH, Rodriguez V, Lew G et al.. “Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.” The Lancet. Haematology (2023). PMID: 37980924 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  71. [71]

    Beyer-Westendorf J, Schellong SM, Gerlach H et al.. “Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.” The Lancet. Haematology (2017). PMID: 28219692 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  72. [72]

    Male C, Lensing AWA, Chan AKC et al.. “Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial.” The Lancet. Haematology (2025). PMID: 40222370 ↗

    L2RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  73. [73]

    Brekelmans MP, Ageno W, Beenen LF et al.. “Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.” The Lancet. Haematology (2016). PMID: 27570090 ↗

    L2RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  74. [74]

    Raskob G, Ageno W, Cohen AT et al.. “Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.” The Lancet. Haematology (2016). PMID: 27132697 ↗

    L2RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  75. [75]

    Monagle P, Cuello CA, Augustine C et al.. “American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.” Blood advances (2018). PMID: 30482766 ↗

    L1GUIDELINECited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  76. [76]

    Bates SM, Rajasekhar A, Middeldorp S et al.. “American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.” Blood advances (2018). PMID: 30482767 ↗

    L1GUIDELINECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  77. [77]

    Piazza G, Bikdeli B, Pandey AK et al.. “Apixaban for Extended Treatment of Provoked Venous Thromboembolism.” The New England journal of medicine (2025). PMID: 40888734 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  78. [78]

    O'Toole RV, Stein DM, O'Hara NN et al.. “Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.” The New England journal of medicine (2023). PMID: 36652352 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  79. [79]

    Weitz JI, Lensing AWA, Prins MH et al.. “Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.” The New England journal of medicine (2017). PMID: 28316279 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  80. [80]

    Devereaux PJ, Marcucci M, Painter TW et al.. “Tranexamic Acid in Patients Undergoing Noncardiac Surgery.” The New England journal of medicine (2022). PMID: 35363452 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors
  81. [81]

    Das Pradhan A, Glynn RJ, Fruchart JC et al.. “Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.” The New England journal of medicine (2022). PMID: 36342113 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management
  82. [82]

    Khorana AA, Soff GA, Kakkar AK et al.. “Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.” The New England journal of medicine (2019). PMID: 30786186 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  83. [83]

    Samama CM, Laporte S, Rosencher N et al.. “Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.” The New England journal of medicine (2020). PMID: 32223113 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 14. Prevention, Screening & Surveillance
  84. [84]

    Willems RAL, van Diepen AE, Dekker EN et al.. “Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41610374 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  85. [85]

    Moik F, Chan WE, Wiedemann S et al.. “Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.” Blood (2021). PMID: 33067632 ↗

    L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 12. Prognosis & Natural History
  86. [86]

    Rogers MAM, Blumberg N, Bernstein SJ et al.. “Association between delivery methods for red blood cell transfusion and the risk of venous thromboembolism: a longitudinal study.” The Lancet. Haematology (2016). PMID: 27818170 ↗

    L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  87. [87]

    Valeriani E, Di Nisio M, Riva N et al.. “Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis.” Blood (2021). PMID: 32911539 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Prognosis & Natural History
  88. [88]

    Couturaud F, Schmidt J, Sanchez O et al.. “Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.” Lancet (London, England) (2025). PMID: 40023651 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  89. [89]

    Ridker PM, Pradhan A, MacFadyen JG et al.. “Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.” Lancet (London, England) (2012). PMID: 22883507 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  90. [90]

    Weitz JI, Kithcart AP, O'Brien MP et al.. “Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.” Lancet (London, England) (2025). PMID: 41218619 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  91. [91]

    Rodger MA, Hague WM, Kingdom J et al.. “Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.” Lancet (London, England) (2014). PMID: 25066248 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 13. Special Populations & Pregnancy
  92. [92]

    Kakkar AK, Brenner B, Dahl OE et al.. “Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.” Lancet (London, England) (2008). PMID: 18582928 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  93. [93]

    Costa LJ, Chhabra S, Medvedova E et al.. “Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34898239 ↗

    L4TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  94. [94]

    Palumbo A, Rajkumar SV, Dimopoulos MA et al.. “Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.” Leukemia (2007). PMID: 18094721 ↗

    L5GUIDELINECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  95. [95]

    Becattini C, Bauersachs R, Maraziti G et al.. “Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.” Haematologica (2022). PMID: 34382385 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  96. [96]

    Mulder FI, Horváth-Puhó E, van Es N et al.. “Venous thromboembolism in cancer patients: a population-based cohort study.” Blood (2021). PMID: 33171494 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History
  97. [97]

    Seng S, Liu Z, Chiu SK et al.. “Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23150697 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  98. [98]

    Chalayer E, Frere C, Daguenet E et al.. “Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40523501 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  99. [99]

    Ward J, Le NQ, Suryakant S et al.. “Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism.” Blood advances (2023). PMID: 37399490 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  100. [100]

    Lin KH, Granka JM, Shastri AJ et al.. “Ancestry-independent risk of venous thromboembolism in individuals with sickle cell trait vs factor V Leiden.” Blood advances (2024). PMID: 39255335 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  101. [101]

    Candeloro M, Valeriani E, Monreal M et al.. “Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis.” Blood advances (2022). PMID: 35613465 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  102. [102]

    Patel P, Patel P, Bhatt M et al.. “Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism.” Blood advances (2021). PMID: 33900385 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  103. [103]

    Kraaijpoel N, Bleker SM, Meyer G et al.. “Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31116676 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  104. [104]

    van Es N, Di Nisio M, Cesarman G et al.. “Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study.” Haematologica (2017). PMID: 28550192 ↗

    L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Prognosis & Natural History
  105. [105]

    Becattini C, Verso M, Muňoz A et al.. “Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients.” Haematologica (2019). PMID: 31171643 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  106. [106]

    Mulder FI, Candeloro M, Kamphuisen PW et al.. “The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.” Haematologica (2019). PMID: 30606788 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  107. [107]

    Orsi FA, Lijfering WM, Geersing GJ et al.. “Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.” British journal of haematology (2021). PMID: 33748963 ↗

    L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors
  108. [108]

    Musallam KM, Tamim HM, Richards T et al.. “Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study.” Lancet (London, England) (2011). PMID: 21982521 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors
  109. [109]

    Jacobs JW, Sharma D, Stephens LD et al.. “Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review.” British journal of haematology (2024). PMID: 38291731 ↗

    L3SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  110. [110]

    Abdulrehman J, Elbaz C, Aziz D et al.. “Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: A systematic review and meta-analysis.” British journal of haematology (2022). PMID: 35877546 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  111. [111]

    Jaspers TCC, Remmelzwaal PC, Weersink EPS et al.. “A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40617505 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  112. [112]

    Danwang C, Temgoua MN, Agbor VN et al.. “Epidemiology of venous thromboembolism in Africa: a systematic review.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28796427 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 13. Special Populations & Pregnancy
  113. [113]

    Young G. “How I treat pediatric venous thromboembolism.” Blood (2017). PMID: 28774877 ↗

    L5CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications, 13. Special Populations & Pregnancy
  114. [114]

    Shet AS, Wun T. “How I diagnose and treat venous thromboembolism in sickle cell disease.” Blood (2018). PMID: 29764840 ↗

    L5CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring
  115. [115]

    Kearon C, Kahn SR. “Long-term treatment of venous thromboembolism.” Blood (2020). PMID: 31917402 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  116. [116]

    Munsch G, Thibord F, Bezerra OC et al.. “Molecular determinants of thrombosis recurrence risk across venous thromboembolism subtypes.” Blood (2025). PMID: 40811855 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 8. Long-term & Definitive Management
  117. [117]

    Francis CW. “Prevention of venous thromboembolism in hospitalized patients with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19704060 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  118. [118]

    Alcalay A, Wun T, Khatri V et al.. “Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16505431 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  119. [119]

    Datta T, Brunson A, Mahajan A et al.. “Racial disparities in cancer-associated thrombosis.” Blood advances (2022). PMID: 35171995 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management, 11. Complications
  120. [120]

    Khan F, Tritschler T, Kahn SR et al.. “Venous thromboembolism.” Lancet (London, England) (2021). PMID: 33984268 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  121. [121]

    Houston BL, McIsaac DI, Breau RH et al.. “Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery.” The New England journal of medicine (2026). PMID: 42267805 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  122. [122]

    Verso M, Moik F, Graziani M et al.. “Targeted anti-cancer agents and risk of venous thromboembolism.” Haematologica (2024). PMID: 39618297 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 12. Prognosis & Natural History
  123. [123]

    Speed V, Roberts LN, Patel JP et al.. “Venous thromboembolism and women's health.” British journal of haematology (2018). PMID: 30334572 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  124. [124]

    Czuprynska J, Arya R. “Annotation: travel and thrombosis.” British journal of haematology (2019). PMID: 31372991 ↗

    L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  125. [125]

    Roberts LN, Patel RK, Arya R. “Venous thromboembolism and ethnicity.” British journal of haematology (2009). PMID: 19552721 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors
  126. [126]

    Dix C, Hunt BJ. “The changing face of cerebral venous sinus thrombosis-emerging new causes and treatments.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39260741 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  127. [127]

    Monnet M, Dufrost V, Wahl D et al.. “Epidemiology, natural history, diagnosis, and management of ovarian vein thrombosis: a scoping review.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39209258 ↗

    L1REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment
  128. [128]

    Winter MP, Schernthaner GH, Lang IM. “Chronic complications of venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28762624 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  129. [129]

    De Stefano V, Ruggeri M, Cervantes F et al.. “High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.” Leukemia (2016). PMID: 27113812 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management
  130. [130]

    Yayac M, Konen T, Parvizi J. “The Use of Intermittent Pneumatic Compression in Orthopaedic Surgery: An Umbrella Review and Meta-Analysis.” JB & JS open access (2026). PMID: 42428035 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications, 12. Prognosis & Natural History
  131. [131]

    Catania S, Caruana C. “A Systematic Review and Meta-Analysis on the Use of Rivaroxaban as Thromboprophylaxis Following Bariatric Surgery.” Obesity surgery (2026). PMID: 42380548 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  132. [132]

    Klein K, Wing SE, Chen L et al.. “The Clinical Net Benefit of Venous Thromboembolism Prophylaxis in Mild-Risk Thrombophilia and Pregnancy: A Systematic Review and Meta-Analysis.” American journal of obstetrics & gynecology MFM (2026). PMID: 42362114 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  133. [133]

    Vosoughi F, Ayati Firoozabadi A, Seyedi D et al.. “Impact of Diabetes Mellitus on Complications and Revision Risk After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis.” Orthopaedic journal of sports medicine (2026). PMID: 42358459 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications, 12. Prognosis & Natural History
  134. [134]

    Kang W, Lam BPY, Lau RTL et al.. “Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.” Drug safety (2026). PMID: 42295501 ↗

    L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  135. [135]

    Key NS, Khorana AA, Kuderer NM et al.. “Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31381464 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  136. [136]

    Lyman GH, Bohlke K, Khorana AA et al.. “Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25605844 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  137. [137]

    Lyman GH, Khorana AA, Kuderer NM et al.. “Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23669224 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  138. [138]

    van der Pol LM, Tromeur C, Bistervels IM et al.. “Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism.” The New England journal of medicine (2019). PMID: 30893534 ↗

    L2TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 13. Special Populations & Pregnancy
  139. [139]

    Levi M, Toh CH, Thachil J et al.. “Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.” British journal of haematology (2009). PMID: 19222477 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 7. Acute & Emergency Management, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  140. [140]

    Watson HG, Keeling DM, Laffan M et al.. “Guideline on aspects of cancer-related venous thrombosis.” British journal of haematology (2015). PMID: 26114207 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  141. [141]

    Sherman DG, Albers GW, Bladin C et al.. “The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.” Lancet (London, England) (2007). PMID: 17448820 ↗

    L1RCTCited in: 4. Clinical Presentation, 14. Prevention, Screening & Surveillance
  142. [142]

    Büller HR, Gallus AS, Pillion G et al.. “Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.” Lancet (London, England) (2011). PMID: 22130488 ↗

    L1RCTCited in: 4. Clinical Presentation
  143. [143]

    Mearns ES, Coleman CI, Patel D et al.. “Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 25819920 ↗

    L1SR_MA_RCTCited in: 4. Clinical Presentation
  144. [144]

    Fronas SG, Dahm AEA, Wik HS et al.. “Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis.” Blood advances (2020). PMID: 32502267 ↗

    L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 7. Acute & Emergency Management
  145. [145]

    Zhang Z, Marcano A, Huisman MV et al.. “Intermittent compression devices as antithrombotic strategy in neurosurgical interventions: a prospective randomized controlled trial (Trial In Prevention of Post-Operative ThromboEmbolic Events).” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40288684 ↗

    L1RCTCited in: 4. Clinical Presentation
  146. [146]

    van der Hulle T, Cheung WY, Kooij S et al.. “Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study.” Lancet (London, England) (2017). PMID: 28549662 ↗

    L2TRIAL_NONRANDOMCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  147. [147]

    Baglin T, Douketis J, Tosetto A et al.. “Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20723032 ↗

    L2SR_OBSCited in: 4. Clinical Presentation
  148. [148]

    Prandoni P, Noventa F, Ghirarduzzi A et al.. “The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.” Haematologica (2007). PMID: 17296569 ↗

    L2COHORTCited in: 4. Clinical Presentation, History and Evolution of Treatment
  149. [149]

    Limperger V, Klostermeier UC, Kenet G et al.. “Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study.” British journal of haematology (2014). PMID: 25039884 ↗

    L2COHORTCited in: 4. Clinical Presentation
  150. [150]

    Limperger V, Kenet G, Goldenberg NA et al.. “Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study.” British journal of haematology (2016). PMID: 27329967 ↗

    L2COHORTCited in: 4. Clinical Presentation
  151. [151]

    Zia A, Goldenberg NA, Rajpurkar M. “How I treat pediatric pulmonary embolism.” Blood (2025). PMID: 40643104 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  152. [152]

    Becattini C, Agnelli G. “Acute treatment of venous thromboembolism.” Blood (2020). PMID: 31917399 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  153. [153]

    Al-Samkari H, Friday C, Kasthuri RS et al.. “Clinical Spectrum of Hereditary Hemorrhagic Telangiectasia: Data from the Comprehensive HHT Outcomes Registry of the US (CHORUS).” Blood (2026). PMID: 41843464 ↗

    L2OTHERCited in: 4. Clinical Presentation
  154. [154]

    Belghasem M, Roth D, Richards S et al.. “Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis.” Blood (2019). PMID: 31877217 ↗

    L5OTHERCited in: 4. Clinical Presentation
  155. [155]

    White C, Noble SIR, Watson M et al.. “Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study.” The Lancet. Haematology (2019). PMID: 30709436 ↗

    L2OTHERCited in: 4. Clinical Presentation
  156. [156]

    Streiff MB. “Diagnosis and initial treatment of venous thromboembolism in patients with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19738109 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  157. [157]

    Galanaud JP, Trujillo-Santos J, Bikdeli B et al.. “Clinical Presentation and Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37471683 ↗

    L2OTHERCited in: 4. Clinical Presentation
  158. [158]

    O'Connell CL, Boswell WD, Duddalwar V et al.. “Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17050877 ↗

    L3OTHERCited in: 4. Clinical Presentation, 6. Staging, Risk Stratification & Prognostic Scoring
  159. [159]

    Steiner D, Staudacher M, Wildner B et al.. “Structured exercise training and rehabilitation in patients with acute venous thromboembolism: a systematic review of randomized controlled trials.” European journal of preventive cardiology (2026). PMID: 41790033 ↗

    L1SR_MA_RCTCited in: 4. Clinical Presentation
  160. [160]

    Esefeld M, Handtke S, Kaiser R et al.. “Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome.” Blood advances (2025). PMID: 40179418 ↗

    L4OTHERCited in: 4. Clinical Presentation, 7. Acute & Emergency Management
  161. [161]

    Prabhakar A, Chatterjee T, Bajaj N et al.. “Venous thrombosis at altitude presents with distinct biochemical profiles: a comparative study from the Himalayas to the plains.” Blood advances (2019). PMID: 31765479 ↗

    L3OTHERCited in: 4. Clinical Presentation
  162. [162]

    Vann RD, Butler FK, Mitchell SJ et al.. “Decompression illness.” Lancet (London, England) (2011). PMID: 21215883 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term & Definitive Management
  163. [163]

    Bourjeily G, Paidas M, Khalil H et al.. “Pulmonary embolism in pregnancy.” Lancet (London, England) (2009). PMID: 19889451 ↗

    L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 13. Special Populations & Pregnancy
  164. [164]

    Alkhatib MN, Abd-Alghafoor T, Elmassry A et al.. “Management of acute ischaemic stroke at Nasser Hospital, Gaza Strip: a clinical audit.” Lancet (London, England) (2018). PMID: 29553426 ↗

    L4OTHERCited in: 4. Clinical Presentation
  165. [165]

    Franchini M, Focosi D, Pezzo MP et al.. “How we manage a high D-dimer.” Haematologica (2024). PMID: 37881856 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 7. Acute & Emergency Management, 8. Long-term & Definitive Management, 13. Special Populations & Pregnancy
  166. [166]

    Ay C, Tengler T, Vormittag R et al.. “Venous thromboembolism--a manifestation of the metabolic syndrome.” Haematologica (2007). PMID: 17339187 ↗

    L3OTHERCited in: 4. Clinical Presentation
  167. [167]

    Imberti D, Agnelli G, Ageno W et al.. “Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.” Haematologica (2008). PMID: 18223291 ↗

    L2OTHERCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management
  168. [168]

    Arya R. “How I manage venous thromboembolism in pregnancy.” British journal of haematology (2011). PMID: 21501137 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 13. Special Populations & Pregnancy
  169. [169]

    El-Amin N, Lauzon SD, Nietert PJ et al.. “Which adults with sickle cell disease need an evaluation for pulmonary embolism?” British journal of haematology (2021). PMID: 34472094 ↗

    L3OTHERCited in: 4. Clinical Presentation
  170. [170]

    Weingarz L, Schwonberg J, Schindewolf M et al.. “Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry.” British journal of haematology (2013). PMID: 24219332 ↗

    L2OTHERCited in: 4. Clinical Presentation
  171. [171]

    Cox C, Roberts LN. “Basics of diagnosis and treatment of venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 39938684 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 12. Prognosis & Natural History
  172. [172]

    Coutinho JM. “Cerebral venous thrombosis.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149030 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
  173. [173]

    Capecchi M, Abbattista M, Martinelli I. “Cerebral venous sinus thrombosis.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29923367 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  174. [174]

    Moragón-Ledesma S, Ortiz-Rodríguez M, Fidalgo-Fernández MÁ et al.. “Executive summary of the consensus document for recommendations on the diagnosis of venous thromboembolism in pregnancy. Recommendations from the Spanish Society of Internal Medicine, the Spanish Society of Medical Radiology, the Spanish Society of Vascular Interventional Radiology, and the Spanish Society of Gynecology and Obstetrics 2025.” Revista clinica espanola (2026). PMID: 41933833 ↗

    L1GUIDELINECited in: 4. Clinical Presentation, 13. Special Populations & Pregnancy
  175. [175]

    Wang Y, Qi L, Sun H et al.. “Dual-Channel Inhibition With Rivaroxaban and Aspirin for Thromboprophylaxis in Patients With Long-Term Inferior Vena Cava Filter Implantation: A Two-Center Cohort Study.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42366998 ↗

    L2COHORTCited in: 4. Clinical Presentation
  176. [176]

    Zhou H, Yin L, Zhang L et al.. “Rare inherited antithrombin deficiency presenting as spontaneous cerebral venous thrombosis with concomitant parenchymal hemorrhage: a case report.” Frontiers in medicine (2026). PMID: 42221117 ↗

    L4CASE_REPORTCited in: 4. Clinical Presentation
  177. [177]

    Ellison AM, Kuppermann N, Shihabuddin BS et al.. “PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study.” The Lancet. Respiratory medicine (2026). PMID: 42398511 ↗

    L2OTHERCited in: 4. Clinical Presentation
  178. [178]

    Zhao L, Fan Z, He J et al.. “The burden and unique patterns of extraintestinal manifestations in Chinese inflammatory bowel disease: a nationwide multicenter investigation.” Clinical and experimental medicine (2026). PMID: 42360371 ↗

    L4OTHERCited in: 4. Clinical Presentation
  179. [179]

    Thomas C, Carere O, Clarfield L et al.. “Indications and Efficacy of Progestogen-Monotherapy as Menopause Hormone Therapy: A Narrative Review.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42347558 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation
  180. [180]

    Prins MH, Lensing AW, Brighton TA et al.. “Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.” The Lancet. Haematology (2014). PMID: 27030066 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  181. [181]

    Amin EE, Ten Cate-Hoek AJ, Bouman AC et al.. “Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis.” The Lancet. Haematology (2018). PMID: 30314712 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  182. [182]

    Cuker A, Arepally GM, Chong BH et al.. “American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.” Blood advances (2018). PMID: 30482768 ↗

    L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  183. [183]

    Lim W, Le Gal G, Bates SM et al.. “American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism.” Blood advances (2018). PMID: 30482764 ↗

    L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  184. [184]

    Liem RI, Lanzkron S, D Coates T et al.. “American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.” Blood advances (2019). PMID: 31794601 ↗

    L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  185. [185]

    Carrier M, Lazo-Langner A, Shivakumar S et al.. “Screening for Occult Cancer in Unprovoked Venous Thromboembolism.” The New England journal of medicine (2015). PMID: 26095467 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  186. [186]

    Brandão LR, Albisetti M, Halton J et al.. “Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.” Blood (2020). PMID: 31805182 ↗

    L2TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  187. [187]

    Ageno W, Camporese G, Riva N et al.. “Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study.” The Lancet. Haematology (2015). PMID: 26686257 ↗

    L2TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  188. [188]

    Klok FA, Toenges G, Mavromanoli AC et al.. “Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.” The Lancet. Haematology (2021). PMID: 34363769 ↗

    L2TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  189. [189]

    Betensky M, Mosha M, Tarango C et al.. “Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial.” Blood advances (2024). PMID: 39321425 ↗

    L2RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  190. [190]

    . “Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.” Lancet (London, England) (2020). PMID: 32050090 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  191. [191]

    Larsen TB, Skjøth F, Kjældgaard JN et al.. “Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.” The Lancet. Haematology (2017). PMID: 28411120 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  192. [192]

    Pelland-Marcotte MC, Tucker C, Klaassen A et al.. “Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study.” The Lancet. Haematology (2019). PMID: 30772417 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  193. [193]

    Søgaard KK, Adelborg K, Darvalics B et al.. “Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study.” The Lancet. Haematology (2018). PMID: 30201587 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  194. [194]

    Zwicker JI, Liebman HA, Bauer KA et al.. “Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).” British journal of haematology (2012). PMID: 23240761 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  195. [195]

    Lam BD, Chrysafi P, Chiasakul T et al.. “Machine learning natural language processing for identifying venous thromboembolism: systematic review and meta-analysis.” Blood advances (2024). PMID: 38522096 ↗

    L1SR_OBSCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History
  196. [196]

    Zhang Y, Begum HA, Grewal H et al.. “Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review.” Blood advances (2022). PMID: 34607343 ↗

    L2SR_OBSCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  197. [197]

    Covut F, Ahmed R, Chawla S et al.. “Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.” British journal of haematology (2021). PMID: 33997961 ↗

    L3TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring
  198. [198]

    Strongman H, Gadd S, Matthews A et al.. “Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.” Lancet (London, England) (2019). PMID: 31443926 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  199. [199]

    Hunt BJ, Parmar K, Horspool K et al.. “The DiPEP (Diagnosis of PE in Pregnancy) biomarker study: An observational cohort study augmented with additional cases to determine the diagnostic utility of biomarkers for suspected venous thromboembolism during pregnancy and puerperium.” British journal of haematology (2018). PMID: 29359796 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 13. Special Populations & Pregnancy
  200. [200]

    Jørgensen H, Horváth-Puhó E, Laugesen K et al.. “Venous thromboembolism and risk of depression: a population-based cohort study.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36696217 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  201. [201]

    Leader A, Wilcox JA, Zwicker JI. “How I treat acute venous thromboembolism in patients with brain tumors.” Blood (2024). PMID: 39197077 ↗

    L5CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 11. Complications
  202. [202]

    Halfdanarson TR, Litzow MR, Murray JA. “Hematologic manifestations of celiac disease.” Blood (2006). PMID: 16973955 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  203. [203]

    Huisman MV, Klok FA. “Current challenges in diagnostic imaging of venous thromboembolism.” Blood (2015). PMID: 26585807 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment
  204. [204]

    Chakraborty R, Rybicki L, Wei W et al.. “Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.” Blood (2022). PMID: 35772005 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  205. [205]

    Dawwas GK, Brown J, Dietrich E et al.. “Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.” The Lancet. Haematology (2018). PMID: 30558988 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  206. [206]

    Ageno W, Mantovani LG, Haas S et al.. “Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.” The Lancet. Haematology (2015). PMID: 26765643 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  207. [207]

    Kearon C, de Wit K, Parpia S et al.. “Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability.” The New England journal of medicine (2019). PMID: 31774957 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  208. [208]

    Kamel H, Navi BB, Sriram N et al.. “Risk of a thrombotic event after the 6-week postpartum period.” The New England journal of medicine (2014). PMID: 24524551 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 7. Acute & Emergency Management
  209. [209]

    Flum DR, Belle SH, King WC et al.. “Perioperative safety in the longitudinal assessment of bariatric surgery.” The New England journal of medicine (2009). PMID: 19641201 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  210. [210]

    Ndumele CE, Rodriguez F, Dixon DL et al.. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology (2026). PMID: 42265997 ↗

    L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  211. [211]

    Ndumele CE, Rodriguez F, Dixon DL et al.. “2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2026). PMID: 42263157 ↗

    L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  212. [212]

    Kuderer NM, Ortel TL, Francis CW. “Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19738120 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  213. [213]

    Khorana AA, Connolly GC. “Assessing risk of venous thromboembolism in the patient with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19720906 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  214. [214]

    Muñoz A, Ay C, Grilz E et al.. “A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36730884 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring
  215. [215]

    Chew HK, Wun T, Harvey DJ et al.. “Incidence of venous thromboembolism and the impact on survival in breast cancer patients.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17194906 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  216. [216]

    Lagerlöf I, Fohlin H, Enblad G et al.. “Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077204 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  217. [217]

    Madenci AL, Weil BR, Liu Q et al.. “Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30216123 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  218. [218]

    Spyropoulos AC. “The management of venous thromboembolism in hospitalized patients with COVID-19.” Blood advances (2020). PMID: 32841342 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  219. [219]

    Anderson DR, Gangaraju R, Sedhom WG et al.. “Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL.” Blood advances (2026). PMID: 41170879 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  220. [220]

    Goldhaber SZ, Bounameaux H. “Pulmonary embolism and deep vein thrombosis.” Lancet (London, England) (2012). PMID: 22494827 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  221. [221]

    Zöller B, Li X, Sundquist J et al.. “Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.” Lancet (London, England) (2011). PMID: 22119579 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  222. [222]

    Bever KM, Masha LI, Sun F et al.. “Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.” Haematologica (2015). PMID: 26452981 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  223. [223]

    Kekre N, Kim HT, Ho VT et al.. “Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation.” Haematologica (2017). PMID: 28341735 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment
  224. [224]

    Zhu T, Ding Q, Bai X et al.. “Normal ranges and genetic variants of antithrombin, protein C and protein S in the general Chinese population. Results of the Chinese Hemostasis Investigation on Natural Anticoagulants Study I Group.” Haematologica (2011). PMID: 21486865 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  225. [225]

    De Stefano V, Za T, Rossi E et al.. “Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.” Haematologica (2008). PMID: 18268279 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  226. [226]

    Rühle F, Stoll M. “Advances in predicting venous thromboembolism risk in children.” British journal of haematology (2017). PMID: 29265336 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  227. [227]

    Wrenn JO, Kabrhel C. “Emergency department diagnosis and management of acute pulmonary embolism.” British journal of haematology (2024). PMID: 39183380 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring, 7. Acute & Emergency Management
  228. [228]

    Rodeghiero F, Ruggeri M. “Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?” British journal of haematology (2012). PMID: 22571181 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 11. Complications
  229. [229]

    Fotiou D, Theodorakakou F, Spiliopoulou S et al.. “Thrombotic and bleeding complications in patients with AL amyloidosis.” British journal of haematology (2024). PMID: 38321638 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  230. [230]

    Langer AL, Togioka B, Smith NA et al.. “Managing anticoagulation peripartum.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41015159 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  231. [231]

    Le Gal G, Righini M. “Controversies in the diagnosis of venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149033 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment
  232. [232]

    Cosmi B. “Management of superficial vein thrombosis.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 25903684 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  233. [233]

    Xiong W, Wang D, Han F et al.. “Extended Rivaroxaban Therapy for Cancer-Associated Low-Risk Pulmonary Embolism by Chemotherapy Status: Insights from the ONCO PE Trial.” Thrombosis and haemostasis (2026). PMID: 42140238 ↗

    L1TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  234. [234]

    Sung J, Chang R, Chen SN et al.. “Obstructive Sleep Apnea and Risk for Thromboembolic Complication Among Patients With Polycystic Ovary Syndrome: A Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 42248807 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  235. [235]

    Wu JY, Lee KW, Huang SC et al.. “Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study.” Frontiers in medicine (2026). PMID: 42239959 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  236. [236]

    Lim MY, Gangaraju R, Jafari O et al.. “Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study.” American journal of hematology (2026). PMID: 42237094 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, History and Evolution of Treatment
  237. [237]

    Ko AK, Milana L, Riva N et al.. “Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42173290 ↗

    L2COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  238. [238]

    Clapham RE, Speed V, Cox C et al.. “Identifying risk factors for venous thromboembolism in medical inpatients: a systematic review and meta-analysis.” Research and practice in thrombosis and haemostasis (2026). PMID: 42318434 ↗

    L2SR_OBSCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  239. [239]

    Betensky M, Azzam M, Bercovitz R et al.. “ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.” Blood advances (2026). PMID: 41949461 ↗

    L1GUIDELINECited in: 6. Staging, Risk Stratification & Prognostic Scoring, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  240. [240]

    Tritschler T, Méan M, Limacher A et al.. “Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model.” Blood (2015). PMID: 26341256 ↗

    L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  241. [241]

    Darzi AJ, Karam SG, Charide R et al.. “Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis.” Blood (2020). PMID: 32092132 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  242. [242]

    Houghton DE, Ashrani A, Liedl D et al.. “Reduced calf muscle pump function is a risk factor for venous thromboembolism: a population-based cohort study.” Blood (2021). PMID: 33657212 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  243. [243]

    Cannegieter SC, Horváth-Puhó E, Schmidt M et al.. “Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study.” Blood (2014). PMID: 25398934 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  244. [244]

    Cieslik J, Mrozinska S, Broniatowska E et al.. “Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study.” Blood (2017). PMID: 29242187 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  245. [245]

    Gade IL, Riddersholm SJ, Christiansen I et al.. “Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study.” Blood advances (2018). PMID: 30425066 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Complications
  246. [246]

    Delluc A, Miranda S, Exter PD et al.. “Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis.” Haematologica (2019). PMID: 31273089 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  247. [247]

    Mahajerin A, Branchford BR, Amankwah EK et al.. “Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models.” Haematologica (2015). PMID: 26001789 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  248. [248]

    Klok FA, Barco S, Turpie AGG et al.. “Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.” British journal of haematology (2018). PMID: 30123981 ↗

    L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  249. [249]

    Tøndel BG, Morelli VM, Hansen JB et al.. “Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35815351 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Complications
  250. [250]

    Horner D, Pandor A, Goodacre S et al.. “Individual risk factors predictive of venous thromboembolism in patients with temporary lower limb immobilization due to injury: a systematic review.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 30580466 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  251. [251]

    Tosetto A, Iorio A, Marcucci M et al.. “Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH).” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22489957 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  252. [252]

    Kraaijpoel N, Carrier M. “How I treat cancer-associated venous thromboembolism.” Blood (2018). PMID: 30478093 ↗

    L5CASE_REPORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Complications, 12. Prognosis & Natural History
  253. [253]

    Khorana AA, Kuderer NM, Culakova E et al.. “Development and validation of a predictive model for chemotherapy-associated thrombosis.” Blood (2008). PMID: 18216292 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  254. [254]

    Pabinger I, van Es N, Heinze G et al.. “A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.” The Lancet. Haematology (2018). PMID: 29885940 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Complications
  255. [255]

    Li A, La J, May SB et al.. “Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36626707 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  256. [256]

    Soff GA. “Cancer-Associated Thrombosis: Management of a Patient With an Isolated Calf Deep Vein Thrombosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38181305 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring
  257. [257]

    Fotopoulou C, duBois A, Karavas AN et al.. “Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18509180 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  258. [258]

    Smith SRM, Morgan NV, Brill A. “Venous thrombosis unchained: Pandora's box of noninflammatory mechanisms.” Blood advances (2025). PMID: 40117491 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring
  259. [259]

    Vladić N, Englisch C, Berger JM et al.. “Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies.” Blood advances (2025). PMID: 40117478 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  260. [260]

    Wolford BN, Zhao QY, Wu KH et al.. “Multipopulation GWAS for venous thromboembolism identifies novel loci followed by experimental validation in zebrafish.” Blood advances (2025). PMID: 40554366 ↗

    L3OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  261. [261]

    Wells PS, Tritschler T, Khan F et al.. “Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism.” Blood advances (2022). PMID: 35679460 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  262. [262]

    Giaccherini C, Marchetti M, Masci G et al.. “Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer.” Haematologica (2019). PMID: 31558668 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  263. [263]

    Potere N, Bertù L, Bucherini E et al.. “Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a post-hoc analysis of the RIDTS trial.” Haematologica (2026). PMID: 42389836 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  264. [264]

    Ay C, Dunkler D, Pirker R et al.. “High D-dimer levels are associated with poor prognosis in cancer patients.” Haematologica (2012). PMID: 22371182 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  265. [265]

    Guimicheva B, Czuprynska J, Arya R. “The prevention of pregnancy-related venous thromboembolism.” British journal of haematology (2014). PMID: 25312482 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  266. [266]

    Prandoni P, Samama MM. “Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients.” British journal of haematology (2008). PMID: 18422787 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring
  267. [267]

    Yuan C, Luo R, Li J et al.. “Development of a machine learning-based predictive model for venous thromboembolism risk assessment in orthopaedic patients with routine prophylaxis.” British journal of haematology (2025). PMID: 40670089 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  268. [268]

    Mora D, Mateo J, Nieto JA et al.. “Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations.” British journal of haematology (2023). PMID: 36942630 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  269. [269]

    Anijs RJS, Nguyen YN, Cannegieter SC et al.. “MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36695398 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring
  270. [270]

    Ten Cate V, Rapp S, Schulz A et al.. “Circulating microRNAs predict recurrence and death following venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37481073 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  271. [271]

    Hamad CD, Wiener J, Shahamatdar S et al.. “Independent and combined associations of cannabis and nicotine use with postoperative outcomes after cervical and lumbar interbody fusion: a retrospective cohort study.” North American Spine Society journal (2026). PMID: 42434720 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 7. Acute & Emergency Management, 11. Complications
  272. [272]

    Zhang J, Cui J, Li F et al.. “Development and validation of a predictive model for postoperative urinary retention following pelvic organ prolapse surgery: a retrospective study.” Frontiers in medicine (2026). PMID: 42422811 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Complications
  273. [273]

    Kim J, Kim TH. “Extended Postoperative Risk of Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Cohort Study.” Spine (2026). PMID: 42308362 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  274. [274]

    Lu J, Sun S, Shang X et al.. “Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.” International journal of medical sciences (2026). PMID: 42328113 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  275. [275]

    Sun T, Chen Y, Shang X et al.. “Risk prediction models for venous thromboembolism in lung cancer patients after surgery: a systematic review and meta-analysis.” Frontiers in oncology (2026). PMID: 42245741 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  276. [276]

    Yang J, Pu Y, Li Y et al.. “Risk prediction models for venous thromboembolism among patients with multiple myeloma: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42222482 ↗

    L1SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  277. [277]

    Li W, Zheng H, Zhen L et al.. “Association between D-dimer difference and risk of postoperative venous thromboembolism in endometrial cancer: a retrospective cohort study.” Thrombosis journal (2026). PMID: 42365345 ↗

    L3COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management
  278. [278]

    Sartori M, Trentini A, Cavara S et al.. “Outcome of catheter associated upper extremity deep vein thrombosis in cancer: A two year prospective study with enoxaparin.” Thrombosis research (2026). PMID: 42322917 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management
  279. [279]

    Al-Samkari H, Karp Leaf RS, Dzik WH et al.. “COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.” Blood (2020). PMID: 32492712 ↗

    L3TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management, 11. Complications
  280. [280]

    Monagle P, Lensing AWA, Thelen K et al.. “Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.” The Lancet. Haematology (2019). PMID: 31420317 ↗

    L4TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management
  281. [281]

    Douillet D, Penaloza A, Viglino D et al.. “Targeted prophylactic anticoagulation based on the TRiP(cast) score in patients with lower limb immobilisation: a multicentre, stepped wedge, randomised implementation trial.” Lancet (London, England) (2024). PMID: 38368901 ↗

    L1RCTCited in: 7. Acute & Emergency Management, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  282. [282]

    Aujesky D, Roy PM, Verschuren F et al.. “Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.” Lancet (London, England) (2011). PMID: 21703676 ↗

    L1RCTCited in: 7. Acute & Emergency Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  283. [283]

    Shah MA, Jhawer M, Ilson DH et al.. “Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 21189380 ↗

    L4TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management, 11. Complications
  284. [284]

    Hill JB, Garcia D, Crowther M et al.. “Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study.” Blood advances (2020). PMID: 33137202 ↗

    L3COHORTCited in: 7. Acute & Emergency Management, 11. Complications
  285. [285]

    Germini F, Zarabi S, Eventov M et al.. “Pulmonary embolism prevalence among emergency department cohorts: A systematic review and meta-analysis by country of study.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 33048461 ↗

    L1SR_OBSCited in: 7. Acute & Emergency Management
  286. [286]

    Barnes GD, Li Y, Gu X et al.. “Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32428998 ↗

    L3COHORTCited in: 7. Acute & Emergency Management
  287. [287]

    Libourel EJ, Klerk CPW, van Norden Y et al.. “Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia.” Blood (2016). PMID: 27354723 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  288. [288]

    Han H, O'Hare C, Joyce E et al.. “JTH in Clinic: management of low-risk pulmonary embolism.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39395541 ↗

    L5CASE_REPORTCited in: 7. Acute & Emergency Management
  289. [289]

    Qdaisat A, Kamal M, Al-Breiki A et al.. “Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients.” Blood advances (2020). PMID: 32311012 ↗

    L3OTHERCited in: 7. Acute & Emergency Management
  290. [290]

    Hariharan N, Brunson A, Mahajan A et al.. “Bleeding in patients with sickle cell disease: a population-based study.” Blood advances (2020). PMID: 32108229 ↗

    L3OTHERCited in: 7. Acute & Emergency Management
  291. [291]

    Kjaergaard J, Bang LE, Sonne-Holm E et al.. “Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism.” Cardiovascular research (2026). PMID: 41610160 ↗

    L1RCTCited in: 7. Acute & Emergency Management
  292. [292]

    Kollias A, Kyriakoulis KG, Dimakakos E et al.. “Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action.” British journal of haematology (2020). PMID: 32304577 ↗

    L5OTHERCited in: 7. Acute & Emergency Management
  293. [293]

    Kline JA, Courtney DM, Kabrhel C et al.. “Prospective multicenter evaluation of the pulmonary embolism rule-out criteria.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18318689 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  294. [294]

    Hisada Y, Archibald SJ, Bansal K et al.. “Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38574862 ↗

    L3OTHERCited in: 7. Acute & Emergency Management
  295. [295]

    Farmakis IT, Christodoulou KC, Hobohm L et al.. “Trends in home treatment and early discharge of patients with low-risk pulmonary embolism.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40107384 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  296. [296]

    Righini M, Perrier A, De Moerloose P et al.. “D-Dimer for venous thromboembolism diagnosis: 20 years later.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18419743 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management
  297. [297]

    Furyes AR, Elmenawi KA, Hackett L et al.. “Is Neighborhood Socioeconomic Deprivation Associated With Outcomes Following Primary THA and TKA? A Systematic Review Utilizing the Area Deprivation Index.” Clinical orthopaedics and related research (2026). PMID: 42275670 ↗

    L2SR_OBSCited in: 7. Acute & Emergency Management, 11. Complications
  298. [298]

    Wang D, Buczacki SJA, Gu Q et al.. “Impact of preoperative weight-loss interventions on outcomes after elective non-bariatric surgery: meta-analysis.” BJS open (2025). PMID: 41739521 ↗

    L1SR_OBSCited in: 7. Acute & Emergency Management
  299. [299]

    Bonsu KO, Chitsike RS, Lee TA et al.. “Clinical effectiveness of a multidisciplinary thrombosis service versus usual care in the management of venous thromboembolism: A retrospective cohort study.” Vascular medicine (London, England) (2026). PMID: 42267761 ↗

    L3COHORTCited in: 7. Acute & Emergency Management
  300. [300]

    Mirahmadi A, Leland CR, Ibrahim IO et al.. “Open reduction and internal fixation vs acute total hip arthroplasty for geriatric acetabular fractures: A multicenter matched cohort study.” Injury (2026). PMID: 41967155 ↗

    L3COHORTCited in: 7. Acute & Emergency Management
  301. [301]

    Srinivas R, Phadke R, Salman S et al.. “Endoscopic versus open lumbar decompression: a retrospective cohort study of 31,000 patients with 90-day follow-up.” Neurosurgical review (2026). PMID: 41721128 ↗

    L2COHORTCited in: 7. Acute & Emergency Management
  302. [302]

    Alshehri AF, Samarkandi WO, Muhanad L et al.. “Meta-analysis of Randomized Trials in Emergency and Acute Orthopedic Trauma Comparing Aspirin and Low-Molecular-Weight Heparin for Thromboprophylaxis.” Orthopedic reviews (2026). PMID: 42405299 ↗

    L1SR_OBSCited in: 7. Acute & Emergency Management, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  303. [303]

    Key NS, Khorana AA, Kuderer NM et al.. “Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37075273 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  304. [304]

    Male C, Lensing AWA, Palumbo JS et al.. “Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.” The Lancet. Haematology (2019). PMID: 31699660 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  305. [305]

    Halton J, Brandão LR, Luciani M et al.. “Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.” The Lancet. Haematology (2020). PMID: 33290737 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  306. [306]

    Skeith L, Malinowski AK, El-Chaâr D et al.. “Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial.” The Lancet. Haematology (2025). PMID: 39827892 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  307. [307]

    Mahé I, Chapelle C, Girard P et al.. “Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.” The Lancet. Haematology (2025). PMID: 41365312 ↗

    L2RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  308. [308]

    Ortel TL, Neumann I, Ageno W et al.. “American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.” Blood advances (2020). PMID: 33007077 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  309. [309]

    Monagle P, Azzam M, Bercovitz R et al.. “American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.” Blood advances (2025). PMID: 40423983 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  310. [310]

    Witt DM, Nieuwlaat R, Clark NP et al.. “American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.” Blood advances (2018). PMID: 30482765 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  311. [311]

    Lyman GH, Carrier M, Ay C et al.. “American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.” Blood advances (2021). PMID: 33570602 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  312. [312]

    Castellucci LA, Chen VM, Kovacs MJ et al.. “Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.” The New England journal of medicine (2026). PMID: 41812192 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  313. [313]

    Yang JC, Lu S, Hayashi H et al.. “Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.” The New England journal of medicine (2025). PMID: 40923797 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  314. [314]

    Agnelli G, Buller HR, Cohen A et al.. “Apixaban for extended treatment of venous thromboembolism.” The New England journal of medicine (2012). PMID: 23216615 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  315. [315]

    Vedantham S, Goldhaber SZ, Julian JA et al.. “Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.” The New England journal of medicine (2017). PMID: 29211671 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  316. [316]

    Agnelli G, Becattini C, Meyer G et al.. “Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.” The New England journal of medicine (2020). PMID: 32223112 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  317. [317]

    Agnelli G, Buller HR, Cohen A et al.. “Oral apixaban for the treatment of acute venous thromboembolism.” The New England journal of medicine (2013). PMID: 23808982 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  318. [318]

    Bauersachs R, Berkowitz SD, Brenner B et al.. “Oral rivaroxaban for symptomatic venous thromboembolism.” The New England journal of medicine (2010). PMID: 21128814 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  319. [319]

    Raskob GE, van Es N, Verhamme P et al.. “Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.” The New England journal of medicine (2017). PMID: 29231094 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  320. [320]

    Büller HR, Décousus H, Grosso MA et al.. “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.” The New England journal of medicine (2013). PMID: 23991658 ↗

    L1RCTCited in: 8. Long-term & Definitive Management
  321. [321]

    Leighl NB, Akamatsu H, Lim SM et al.. “Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38857463 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  322. [322]

    Young AM, Marshall A, Thirlwall J et al.. “Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29746227 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  323. [323]

    Korst CLBM, Plattel W, de Kort EA et al.. “Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.” The Lancet. Haematology (2026). PMID: 41482445 ↗

    L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management
  324. [324]

    Connor P, Sánchez van Kammen M, Lensing AWA et al.. “Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).” Blood advances (2020). PMID: 33351120 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  325. [325]

    Mulder FI, Bosch FTM, Young AM et al.. “Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.” Blood (2020). PMID: 32396939 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History
  326. [326]

    Kunutsor SK, Seidu S, Khunti K. “Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.” The Lancet. Haematology (2017). PMID: 28089655 ↗

    L2SR_OBSCited in: 8. Long-term & Definitive Management, 14. Prevention, Screening & Surveillance
  327. [327]

    Klemen ND, Feingold PL, Hashimoto B et al.. “Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis.” The Lancet. Haematology (2020). PMID: 32735837 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management
  328. [328]

    Schünemann HJ, Ventresca M, Crowther M et al.. “Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis.” The Lancet. Haematology (2020). PMID: 32976752 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  329. [329]

    Alikhan R, Gomez K, Maraveyas A et al.. “Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology Guideline.” British journal of haematology (2024). PMID: 38664942 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  330. [330]

    Danese S, Vermeire S, Zhou W et al.. “Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.” Lancet (London, England) (2022). PMID: 35644166 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications
  331. [331]

    Bistervels IM, Buchmüller A, Wiegers HMG et al.. “Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.” Lancet (London, England) (2022). PMID: 36354038 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  332. [332]

    McBane RD, Loprinzi CL, Zemla T et al.. “Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38537780 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  333. [333]

    McBane RD, Wysokinski WE, Le-Rademacher JG et al.. “Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31630479 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  334. [334]

    Hamulyák EN, Daams JG, Leebeek FWG et al.. “A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.” Blood advances (2021). PMID: 33570633 ↗

    L2SR_OBSCited in: 8. Long-term & Definitive Management
  335. [335]

    Young G, Lensing AWA, Monagle P et al.. “Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32246743 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  336. [336]

    Giossi R, Menichelli D, D'Amico F et al.. “Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37481075 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  337. [337]

    Bhat RV, Young G, Sharathkumar AA. “How I treat pediatric venous thromboembolism in the DOAC era.” Blood (2024). PMID: 37390311 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  338. [338]

    Gailani D, Gruber A. “Targeting factor XI and factor XIa to prevent thrombosis.” Blood (2024). PMID: 38142404 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  339. [339]

    Witmer C, Raffini L. “Treatment of venous thromboembolism in pediatric patients.” Blood (2020). PMID: 31917400 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  340. [340]

    Weitz JI, Chan NC. “Novel antithrombotic strategies for treatment of venous thromboembolism.” Blood (2020). PMID: 31917385 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  341. [341]

    Lee AY, Peterson EA. “Treatment of cancer-associated thrombosis.” Blood (2013). PMID: 23843493 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  342. [342]

    Garcia D, Libby E, Crowther MA. “The new oral anticoagulants.” Blood (2009). PMID: 19880491 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 14. Prevention, Screening & Surveillance
  343. [343]

    Middeldorp S, Nieuwlaat R, Baumann Kreuziger L et al.. “American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.” Blood advances (2023). PMID: 37195076 ↗

    L1OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  344. [344]

    Di Nisio M, van Es N, Büller HR. “Deep vein thrombosis and pulmonary embolism.” Lancet (London, England) (2016). PMID: 27375038 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  345. [345]

    Quenby S, Gallos ID, Dhillon-Smith RK et al.. “Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss.” Lancet (London, England) (2021). PMID: 33915094 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Complications, 13. Special Populations & Pregnancy
  346. [346]

    Ghanima W, Cooper N, Rodeghiero F et al.. “Thrombopoietin receptor agonists: ten years later.” Haematologica (2019). PMID: 31073079 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  347. [347]

    Tran A, Lutsey PL, Carrier M. “Minor trauma and venous thromboembolism: the threshold for antithrombotic prophylaxis.” Haematologica (2024). PMID: 39618296 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  348. [348]

    Birenboim SB, Rabinowicz R. “Acute therapy-related toxicities in pediatric acute lymphoblastic leukemia.” Haematologica (2025). PMID: 40045890 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  349. [349]

    Migliacci R, Becattini C, Pesavento R et al.. “Endothelial dysfunction in patients with spontaneous venous thromboembolism.” Haematologica (2007). PMID: 17550854 ↗

    L3OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  350. [350]

    Sanfilippo KM, Moik F, Candeloro M et al.. “Unanswered questions in cancer-associated thrombosis.” British journal of haematology (2022). PMID: 35611985 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  351. [351]

    Barsam SJ, Patel R, Arya R. “Anticoagulation for prevention and treatment of cancer-related venous thromboembolism.” British journal of haematology (2013). PMID: 23560605 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  352. [352]

    Roberts LN, Thachil J. “Prevention and management of venous thrombosis in patients with cirrhosis.” British journal of haematology (2024). PMID: 39186931 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  353. [353]

    Scott G, Mahdi AJ, Alikhan R. “Superficial vein thrombosis: a current approach to management.” British journal of haematology (2014). PMID: 25521017 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  354. [354]

    Abdou JK, Auyeung V, Patel JP et al.. “Adherence to long-term anticoagulation treatment, what is known and what the future might hold.” British journal of haematology (2016). PMID: 27173746 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  355. [355]

    de Jong PG, Coppens M, Middeldorp S. “Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.” British journal of haematology (2012). PMID: 22734929 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  356. [356]

    Martin KA, Beyer-Westendorf J, Davidson BL et al.. “Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34259389 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  357. [357]

    Falanga A, Marchetti M. “Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36931602 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  358. [358]

    Vedantham S. “Interventional therapy for venous thromboembolism.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149031 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  359. [359]

    Dimopoulos MA, Leleu X, Palumbo A et al.. “Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.” Leukemia (2014). PMID: 24496300 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Complications, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  360. [360]

    Dimopoulos MA, Palumbo A, Attal M et al.. “Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.” Leukemia (2011). PMID: 21293488 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  361. [361]

    Hoveidaei AH, Niakan R, Salmannezhad A et al.. “The Efficacy and Safety of Tranexamic Acid in Revision Total Knee and Total Hip Arthroplasty: A Systematic Review and Meta-Analysis.” Arthroplasty today (2026). PMID: 42382163 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  362. [362]

    Tang J, Zheng Y, Pan L et al.. “Thrombotic outcomes and mortality with roxadustat for anemia in chronic kidney disease: a systematic review and meta-analysis of randomized trials.” Frontiers in pharmacology (2026). PMID: 42358369 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  363. [363]

    Zhou L, Ma X, Wang Z et al.. “Comparable Efficacy of Two Anticoagulant Strategies Following Total Hip Replacement in Elderly Patients: A Prospective Randomised Controlled Trial.” Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2026). PMID: 42403128 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 13. Special Populations & Pregnancy
  364. [364]

    Delrue M, Crichi B, Crassard I et al.. “Direct oral anticoagulants versus vitamin K antagonists for the treatment of cerebral venous thrombosis: A systematic review and meta-analysis of randomized clinical trials.” Thrombosis research (2026). PMID: 42361491 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management
  365. [365]

    Talerico R, Cavallaro C, Iorio M et al.. “Bleeding risk in patients receiving concurrent treatment with direct oral anticoagulants and corticosteroids: A systematic review.” Thrombosis research (2026). PMID: 42320245 ↗

    L2SR_OBSCited in: 8. Long-term & Definitive Management
  366. [366]

    Santini P, Santagata D, Mosoni C et al.. “Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.” Seminars in thrombosis and hemostasis (2026). PMID: 42379243 ↗

    L3COHORTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  367. [367]

    Strijdhorst A, Salet DM, Schoenaker JM et al.. “Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.” Research and practice in thrombosis and haemostasis (2026). PMID: 42328266 ↗

    L2COHORTCited in: 8. Long-term & Definitive Management
  368. [368]

    Parvataneni HK, Gray CF, Prieto HA et al.. “Clinical and psychosocial impact of limited mobility during the interstage period of two-stage revision arthroplasty for prosthetic joint infection: a state-of-the-art review.” Journal of orthopaedic surgery and research (2026). PMID: 42432721 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  369. [369]

    Chalayer E, Talbot A, Frenzel L et al.. “Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35557490 ↗

    L2RCTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  370. [370]

    Gerber DE, Segal JB, Levy MY et al.. “The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.” Blood (2008). PMID: 18480425 ↗

    L3OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  371. [371]

    Armenian SH, Chen Y, Hageman L et al.. “Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35731989 ↗

    L3OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  372. [372]

    Gangaraju R, Chen Y, Hageman L et al.. “Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model.” Blood advances (2021). PMID: 34461633 ↗

    L3OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  373. [373]

    Martens KL, da Costa WL, Amos CI et al.. “HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment.” Blood advances (2021). PMID: 33570631 ↗

    L3OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  374. [374]

    Hashmi H, Mirza AS, Darwin A et al.. “Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma.” Blood advances (2020). PMID: 32877523 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  375. [375]

    Deng RX, Zhu XL, Zhang AB et al.. “Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients.” Transplantation and cellular therapy (2022). PMID: 36272528 ↗

    L3RCTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  376. [376]

    Ahya VN, McShane PJ, Baz MA et al.. “Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2010). PMID: 20947384 ↗

    L2RCTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  377. [377]

    Gonsalves A, Carrier M, Wells PS et al.. “Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18627443 ↗

    L3OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  378. [378]

    Buchbinder N, Wallyn F, Lhuillier E et al.. “[Post-transplant pulmonary complications: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].” Bulletin du cancer (2018). PMID: 30595221 ↗

    L1GUIDELINECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  379. [379]

    Chitkara A, Sreenivasan S, Yin Y et al.. “Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials.” Current oncology (Toronto, Ont.) (2024). PMID: 39195306 ↗

    L1TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  380. [380]

    Vergis N, Phillips R, Cornelius V et al.. “Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.” Trials (2021). PMID: 33845867 ↗

    L5TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  381. [381]

    Zahid MF, Murad MH, Litzow MR et al.. “Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.” Annals of hematology (2016). PMID: 27103008 ↗

    L1SR_OBSCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  382. [382]

    Raymond C. “Venous and arterial thrombosis following extracorporeal photopheresis: A descriptive cohort study using a federated electronic health record network.” Transfusion (2026). PMID: 42313400 ↗

    L3COHORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  383. [383]

    Juul MB, Jelicic J, Anru PL et al.. “Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.” Leukemia & lymphoma (2022). PMID: 35437098 ↗

    L2COHORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  384. [384]

    Xia Y, Tang L, Hu Y. “The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.” Technology and health care : official journal of the European Society for Engineering and Medicine (2023). PMID: 37545264 ↗

    L1SR_OBSCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  385. [385]

    Erickson K, Powers ME. “Factor V leiden thrombophilia in a female collegiate soccer athlete: a case report.” Journal of athletic training (2013). PMID: 23675803 ↗

    L4CASE_REPORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  386. [386]

    Soo RA, Fernandez-Penas P, Li M et al.. “Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42048802 ↗

    L1REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  387. [387]

    Cuker A, Tseng EK, Nieuwlaat R et al.. “American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.” Blood advances (2021). PMID: 34474482 ↗

    L1GUIDELINECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  388. [388]

    Cuker A, Tseng EK, Nieuwlaat R et al.. “American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis.” Blood advances (2022). PMID: 34727173 ↗

    L1GUIDELINECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  389. [389]

    Carrier M, Abou-Nassar K, Mallick R et al.. “Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.” The New England journal of medicine (2018). PMID: 30511879 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  390. [390]

    Arabi YM, Al-Hameed F, Burns KEA et al.. “Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis.” The New England journal of medicine (2019). PMID: 30779530 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  391. [391]

    van Adrichem RA, Nemeth B, Algra A et al.. “Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting.” The New England journal of medicine (2016). PMID: 27959702 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  392. [392]

    Spyropoulos AC, Ageno W, Albers GW et al.. “Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.” The New England journal of medicine (2018). PMID: 30145946 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  393. [393]

    Palumbo JS, Lensing AWA, Brandão LR et al.. “Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr.” Blood advances (2022). PMID: 36006613 ↗

    L2RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  394. [394]

    Tang L, Wu YY, Lip GY et al.. “Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis.” The Lancet. Haematology (2015). PMID: 26765646 ↗

    L1SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  395. [395]

    Lassen MR, Raskob GE, Gallus A et al.. “Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.” Lancet (London, England) (2010). PMID: 20206776 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  396. [396]

    Turpie AG, Lassen MR, Davidson BL et al.. “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.” Lancet (London, England) (2009). PMID: 19411100 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  397. [397]

    Ramacciotti E, Barile Agati L, Calderaro D et al.. “Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.” Lancet (London, England) (2021). PMID: 34921756 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  398. [398]

    Devereaux PJ, Duceppe E, Guyatt G et al.. “Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.” Lancet (London, England) (2018). PMID: 29900874 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  399. [399]

    Lyman GH, Khorana AA, Falanga A et al.. “American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17968019 ↗

    L1SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  400. [400]

    Kawtharany H, Azzam M, Alkhader A et al.. “Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis.” Blood advances (2025). PMID: 40561511 ↗

    L1SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  401. [401]

    Kusne Y, Ghorbanzadeh A, Dulau-Florea A et al.. “Venous and arterial thrombosis in patients with VEXAS syndrome.” Blood (2024). PMID: 38306657 ↗

    L4OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  402. [402]

    Sochet AA, Kiskaddon A, Goldenberg NA. “How I approach pharmacological thromboprophylaxis in children.” Blood (2025). PMID: 39899879 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  403. [403]

    Gerber DE, Grossman SA, Streiff MB. “Management of venous thromboembolism in patients with primary and metastatic brain tumors.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16525187 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  404. [404]

    Paciullo F, Bury L, Noris P et al.. “Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study.” Haematologica (2019). PMID: 31558677 ↗

    L4OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  405. [405]

    Shet AS, Lizarralde-Iragorri MA, Naik RP. “The molecular basis for the prothrombotic state in sickle cell disease.” Haematologica (2020). PMID: 33054077 ↗

    L5OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  406. [406]

    Stevens H, Ho WWH, Singh M et al.. “Prothrombotic genetic variants and cancer-associated venous thromboembolism: defining thrombotic risk across tumor types.” Haematologica (2026). PMID: 42095241 ↗

    L2OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  407. [407]

    Ferroni P, Guadagni F, Riondino S et al.. “Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy.” Haematologica (2014). PMID: 25085351 ↗

    L2OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  408. [408]

    Roberts LN, Arya R, Hunt BJ. “Advances and current research in primary thromboprophylaxis to prevent hospital-associated venous thromboembolism.” British journal of haematology (2024). PMID: 38577829 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  409. [409]

    Keeling D, Alikhan R. “Management of venous thromboembolism--controversies and the future.” British journal of haematology (2013). PMID: 23531017 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  410. [410]

    Jones A, Swan D, Lisman T et al.. “Anticoagulation in chronic kidney disease: current status and future perspectives.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37778512 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  411. [411]

    Barbar S, Noventa F, Rossetto V et al.. “A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20738765 ↗

    L2OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  412. [412]

    Kidder E, Dhanesha N. “Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.” Current opinion in hematology (2026). PMID: 42348666 ↗

    L5TRIAL_NONRANDOMCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  413. [413]

    Hershfeld B, Le J, Xie K et al.. “Optimal Route of Tranexamic Acid Administration in Total Knee Arthroplasty: A Bayesian Network Meta-Analysis With Decision-Analytic Cost Evaluation.” The Journal of arthroplasty (2026). PMID: 42373027 ↗

    L1SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  414. [414]

    Kounoudi C, Serraou EA, Stathopoulou M et al.. “Systematic Review and Meta-analysis on the Efficacy and Safety of Low Dose Anticoagulation Compared with Therapeutic Dose in the Extended Secondary Prophylaxis of Venous Thromboembolism.” European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery (2026). PMID: 42320637 ↗

    L1SR_OBSCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  415. [415]

    Arakaki D, Iwata M, Terasawa T. “Association between intermittent pneumatic compression use and deep vein thrombosis in hospitalized adult medical patients: a retrospective single-center case-cohort study in Japan.” Thrombosis journal (2026). PMID: 42393717 ↗

    L3COHORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  416. [416]

    Schünemann HJ, Cushman M, Burnett AE et al.. “American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.” Blood advances (2018). PMID: 30482763 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  417. [417]

    Eikelboom JW, Mazzarol A, Quinlan DJ et al.. “Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.” Haematologica (2004). PMID: 15136222 ↗

    L2GUIDELINECited in: History and Evolution of Treatment
  418. [418]

    Pengo V, Denas G, Zoppellaro G et al.. “Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.” Blood (2018). PMID: 30002145 ↗

    L1RCTCited in: History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  419. [419]

    Becattini C, Pace U, Pirozzi F et al.. “Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer.” Blood (2022). PMID: 35580191 ↗

    L1RCTCited in: History and Evolution of Treatment
  420. [420]

    Cohen H, Hunt BJ, Efthymiou M et al.. “Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.” The Lancet. Haematology (2016). PMID: 27570089 ↗

    L1RCTCited in: History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  421. [421]

    Raskob GE, van Es N, Segers A et al.. “Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.” The Lancet. Haematology (2016). PMID: 27476789 ↗

    L2RCTCited in: History and Evolution of Treatment
  422. [422]

    Li A, Khatib R, Lopes LC et al.. “Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.” Blood advances (2025). PMID: 40198201 ↗

    L1SR_OBSCited in: History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  423. [423]

    Macbeth F, Noble S, Evans J et al.. “Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26700124 ↗

    L1RCTCited in: History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History
  424. [424]

    Khorana AA, Kamphuisen PW, Meyer G et al.. “Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28029329 ↗

    L2RCTCited in: History and Evolution of Treatment
  425. [425]

    Lee AY, Rickles FR, Julian JA et al.. “Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005). PMID: 15699480 ↗

    L2RCTCited in: History and Evolution of Treatment
  426. [426]

    Verso M, Agnelli G, Bertoglio S et al.. “Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005). PMID: 15767643 ↗

    L1RCTCited in: History and Evolution of Treatment
  427. [427]

    van Doormaal FF, Di Nisio M, Otten HM et al.. “Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21502549 ↗

    L1RCTCited in: History and Evolution of Treatment
  428. [428]

    Mant MJ, O'Brien BD, Thong KL et al.. “Haemorrhagic complications of heparin therapy.” Lancet (London, England) (1977). PMID: 68228 ↗

    L2RCTCited in: History and Evolution of Treatment
  429. [429]

    Cohen AT, Tapson VF, Bergmann JF et al.. “Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study.” Lancet (London, England) (2008). PMID: 18242412 ↗

    L2RCTCited in: History and Evolution of Treatment
  430. [430]

    Wu O, Robertson L, Twaddle S et al.. “Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis.” British journal of haematology (2005). PMID: 16173967 ↗

    L2SR_OBSCited in: History and Evolution of Treatment
  431. [431]

    Scaglione L, Piobbici M, Pagano E et al.. “Implementing guidelines for venous thromboembolism prophylaxis in a large Italian teaching hospital: lights and shadows.” Haematologica (2005). PMID: 15921383 ↗

    L2RCTCited in: History and Evolution of Treatment
  432. [432]

    Couturaud F, Pernod G, Presles E et al.. “Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial.” Haematologica (2019). PMID: 30606789 ↗

    L1RCTCited in: History and Evolution of Treatment
  433. [433]

    Schol-Gelok S, de Maat MPM, Biedermann JS et al.. “Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.” British journal of haematology (2020). PMID: 32301122 ↗

    L2RCTCited in: History and Evolution of Treatment
  434. [434]

    Bradbury C, Fletcher K, Sun Y et al.. “A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study).” British journal of haematology (2019). PMID: 31713863 ↗

    L1RCTCited in: History and Evolution of Treatment
  435. [435]

    Hirsh J, O'Donnell M, Weitz JI. “New anticoagulants.” Blood (2004). PMID: 15191946 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  436. [436]

    Middeldorp S, Ganzevoort W. “How I treat venous thromboembolism in pregnancy.” Blood (2020). PMID: 32797192 ↗

    L5CASE_REPORTCited in: History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  437. [437]

    Pabinger I, Thaler J. “How I treat patients with hereditary antithrombin deficiency.” Blood (2019). PMID: 31697819 ↗

    L5CASE_REPORTCited in: History and Evolution of Treatment
  438. [438]

    Gouin-Thibault I, Frere C, Castellucci LA et al.. “How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42162738 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  439. [439]

    Pini M, Marchini L, Giordano A. “Diagnostic strategies in venous thromboembolism.” Haematologica (1999). PMID: 10366798 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  440. [440]

    Samama MM, Dahl OE, Quinlan DJ et al.. “Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.” Haematologica (2003). PMID: 14687996 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  441. [441]

    Ruggeri M, Milan M, La Greca G et al.. “Adult patients with the nephrotic syndrome: really at high risk for deep venous thromboembolism? Report of a series and review of the literature.” Haematologica (1993). PMID: 8039758 ↗

    L4REVIEW_NARRATIVECited in: History and Evolution of Treatment
  442. [442]

    Lecumberri R, Páramo JA, Rocha E. “Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies.” Haematologica (2005). PMID: 16154849 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  443. [443]

    Brenner B, Papadakis E, Greer IA et al.. “Assessment-based management of placenta-mediated pregnancy complications: Pragmatism until a precision medicine approach evolves.” British journal of haematology (2023). PMID: 37169354 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  444. [444]

    Lee AY. “Management of thrombosis in cancer: primary prevention and secondary prophylaxis.” British journal of haematology (2005). PMID: 15667530 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  445. [445]

    Lang I. “Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension.” British journal of haematology (2010). PMID: 20331466 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  446. [446]

    Iba T, Helms J, Levi M et al.. “Thromboinflammation in acute injury: infections, heatstroke, and trauma.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37541590 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  447. [447]

    Ginsberg JS, Wells PS, Brill-Edwards P et al.. “Antiphospholipid antibodies and venous thromboembolism.” Blood (1995). PMID: 7579334 ↗

    L2OTHERCited in: History and Evolution of Treatment
  448. [448]

    Burdett KB, Unruh D, Drumm M et al.. “Determining venous thromboembolism risk in patients with adult-type diffuse glioma.” Blood (2023). PMID: 36399711 ↗

    L3OTHERCited in: History and Evolution of Treatment
  449. [449]

    Joshi DK, Kirmani N, Coy Z et al.. “Reduced-Dose vs Full-Dose Direct Oral Anticoagulants for Extended Anticoagulation Therapy in Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of the Society for Cardiovascular Angiography & Interventions (2026). PMID: 42183132 ↗

    L1SR_MA_RCTCited in: History and Evolution of Treatment
  450. [450]

    Spiazzi BF, Brennan D, Zingano CP et al.. “Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial.” JAMA cardiology (2026). PMID: 42201706 ↗

    L2RCTCited in: History and Evolution of Treatment
  451. [451]

    Okumura K, Akao M, Fukuzawa M et al.. “Association of Edoxaban Pharmacokinetics With Bleeding in Older Patients With Atrial Fibrillation Treated With Low-Dose Edoxaban: A Post Hoc Analysis of a Randomized Controlled Trial.” Journal of the American Heart Association (2026). PMID: 42132160 ↗

    L2RCTCited in: History and Evolution of Treatment
  452. [452]

    Bagot CN, Arya R. “Virchow and his triad: a question of attribution.” British journal of haematology (2008). PMID: 18783400 ↗

    L5OTHERCited in: History and Evolution of Treatment
  453. [453]

    Kobelt K, Biasiutti FD, Mattle HP et al.. “Protein Z in ischaemic stroke.” British journal of haematology (2001). PMID: 11472363 ↗

    L3OTHERCited in: History and Evolution of Treatment
  454. [454]

    Shang H, Jiang JY, Guffey D et al.. “Natural history of cancer-associated splanchnic vein thrombosis.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38309433 ↗

    L2OTHERCited in: History and Evolution of Treatment
  455. [455]

    . “[Comprehensive rehabilitation guideline for lung transplantation].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2026). PMID: 42236453 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  456. [456]

    Kakkar AK, Cimminiello C, Goldhaber SZ et al.. “Low-molecular-weight heparin and mortality in acutely ill medical patients.” The New England journal of medicine (2011). PMID: 22204723 ↗

    L1RCTCited in: 11. Complications
  457. [457]

    Dimopoulos MA, Palumbo A, Corradini P et al.. “Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.” Blood (2016). PMID: 27226434 ↗

    L4TRIAL_NONRANDOMCited in: 11. Complications
  458. [458]

    Vonderheide RH, Flaherty KT, Khalil M et al.. “Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17327609 ↗

    L4TRIAL_NONRANDOMCited in: 11. Complications
  459. [459]

    Sultan AA, Tata LJ, West J et al.. “Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom.” Blood (2013). PMID: 23550034 ↗

    L2COHORTCited in: 11. Complications
  460. [460]

    Abdul Sultan A, Grainge MJ, West J et al.. “Impact of risk factors on the timing of first postpartum venous thromboembolism: a population-based cohort study from England.” Blood (2014). PMID: 25157182 ↗

    L2COHORTCited in: 11. Complications
  461. [461]

    Darzi AJ, Karam SG, Spencer FA et al.. “Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment.” Blood advances (2020). PMID: 32542391 ↗

    L2SR_OBSCited in: 11. Complications
  462. [462]

    Neumann I, Izcovich A, Zhang Y et al.. “DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines.” Blood advances (2020). PMID: 32289163 ↗

    L1SR_OBSCited in: 11. Complications
  463. [463]

    Sibai H, Chen R, Liu X et al.. “Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.” British journal of haematology (2020). PMID: 32395867 ↗

    L2TRIAL_NONRANDOMCited in: 11. Complications
  464. [464]

    Quach H, Fernyhough L, Henderson R et al.. “Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.” British journal of haematology (2017). PMID: 28197996 ↗

    L4TRIAL_NONRANDOMCited in: 11. Complications
  465. [465]

    Thomas W, Foukaneli T, Cosgrove J et al.. “Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases.” British journal of haematology (2021). PMID: 33954989 ↗

    L4TRIAL_NONRANDOMCited in: 11. Complications
  466. [466]

    Grainge MJ, West J, Card TR. “Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.” Lancet (London, England) (2010). PMID: 20149425 ↗

    L3COHORTCited in: 11. Complications
  467. [467]

    Di Nisio M, Candeloro M, Rutjes AWS et al.. “Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29754426 ↗

    L2SR_OBSCited in: 11. Complications, 14. Prevention, Screening & Surveillance
  468. [468]

    Santagata D, Abenante A, Squizzato A et al.. “Rates of venous thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital hemophilia A or B: a systematic review.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38215910 ↗

    L2SR_OBSCited in: 11. Complications
  469. [469]

    Zidane M, van Hulsteijn LH, Brenninkmeijer BJ et al.. “Out of hospital treatment with subcutaneous low molecular weight heparin in patients with acute deep-vein thrombosis: a prospective study in daily practice.” Haematologica (2006). PMID: 16885045 ↗

    L4COHORTCited in: 11. Complications
  470. [470]

    Oteng-Ntim E, Ayensah B, Knight M et al.. “Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease.” British journal of haematology (2014). PMID: 25522142 ↗

    L2COHORTCited in: 11. Complications
  471. [471]

    Lanting VR, Bosch FTM, Martens ESL et al.. “Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40915572 ↗

    L2COHORTCited in: 11. Complications
  472. [472]

    Krupa-Zabiegała J, Michel PS, Stępień K et al.. “Higher citrullinated histone H3 is associated with postthrombotic syndrome: a cohort study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41192568 ↗

    L2COHORTCited in: 11. Complications
  473. [473]

    Skeith L, Bates SM. “Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk.” The New England journal of medicine (2026). PMID: 41985134 ↗

    L5REVIEW_NARRATIVECited in: 11. Complications
  474. [474]

    Khorana AA, Streiff MB, Farge D et al.. “Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19720907 ↗

    L1REVIEW_NARRATIVECited in: 11. Complications
  475. [475]

    Lau BD, Bhave A, Yui JC et al.. “Inaccuracies of venous thromboembolism risk assessment and prevention practices among medically ill patients.” Blood advances (2025). PMID: 40408310 ↗

    L2OTHERCited in: 11. Complications
  476. [476]

    Smeeth L, Cook C, Thomas S et al.. “Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.” Lancet (London, England) (2006). PMID: 16581406 ↗

    L4OTHERCited in: 11. Complications
  477. [477]

    Paulsen B, Skille H, Smith EN et al.. “Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism.” Haematologica (2019). PMID: 31582554 ↗

    L3OTHERCited in: 11. Complications
  478. [478]

    Grimnes G, Isaksen T, Tichelaar YIGV et al.. “C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover study.” Haematologica (2018). PMID: 29674505 ↗

    L3OTHERCited in: 11. Complications
  479. [479]

    Grilz E, Königsbrügge O, Posch F et al.. “Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.” Haematologica (2018). PMID: 29794142 ↗

    L2OTHERCited in: 11. Complications
  480. [480]

    Englisch C, Moik F, Thaler J et al.. “Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.” Haematologica (2024). PMID: 37822244 ↗

    L2OTHERCited in: 11. Complications
  481. [481]

    Hunt BJ. “The prevention of hospital-acquired venous thromboembolism in the United Kingdom.” British journal of haematology (2008). PMID: 19076173 ↗

    L5REVIEW_NARRATIVECited in: 11. Complications
  482. [482]

    Al-Rubaish S, Awad A, Mehros W et al.. “Efficacy and safety of apixaban versus enoxaparin in gynecologic oncology surgery: a systematic review and meta-analysis.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 42284982 ↗

    L1SR_OBSCited in: 11. Complications
  483. [483]

    Singh M, Labrom F, Bigwood J et al.. “Robotic-assisted total knee arthroplasty does not increase procedure duration or adverse event incidence: a retrospective comparative cohort study in a secondary public hospital.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026). PMID: 42406084 ↗

    L2COHORTCited in: 11. Complications
  484. [484]

    Robertson L, Wu O, Langhorne P et al.. “Thrombophilia in pregnancy: a systematic review.” British journal of haematology (2006). PMID: 16398652 ↗

    L2SR_OBSCited in: 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  485. [485]

    Reitter S, Laczkovics C, Waldhoer T et al.. “Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women.” Haematologica (2010). PMID: 20511663 ↗

    L2COHORTCited in: 12. Prognosis & Natural History
  486. [486]

    Hisada Y, Mackman N. “Cancer-associated pathways and biomarkers of venous thrombosis.” Blood (2017). PMID: 28807983 ↗

    L5REVIEW_NARRATIVECited in: 12. Prognosis & Natural History
  487. [487]

    Zöller B, Connors JM. “Multimorbidity, comorbidity, frailty, and venous thromboembolism.” Haematologica (2024). PMID: 39618295 ↗

    L5REVIEW_NARRATIVECited in: 12. Prognosis & Natural History
  488. [488]

    Rodriguez V, O'Brien SH, Orgel E et al.. “Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia.” Blood advances (2025). PMID: 40505060 ↗

    L1RCTCited in: 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  489. [489]

    Abbattista M, Gianniello F, Novembrino C et al.. “Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study.” The Lancet. Haematology (2020). PMID: 32112716 ↗

    L2COHORTCited in: 13. Special Populations & Pregnancy
  490. [490]

    Wiegers HMG, Körmendiné Farkas D, Horváth-Puhó E et al.. “Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study.” The Lancet. Haematology (2023). PMID: 36972715 ↗

    L2COHORTCited in: 13. Special Populations & Pregnancy
  491. [491]

    Liu N, Vigod SN, Farrugia MM et al.. “Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in Canada.” The Lancet. Haematology (2018). PMID: 29891177 ↗

    L2COHORTCited in: 13. Special Populations & Pregnancy
  492. [492]

    McRae S, Tran H, Schulman S et al.. “Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.” Lancet (London, England) (2006). PMID: 16876665 ↗

    L2SR_OBSCited in: 13. Special Populations & Pregnancy
  493. [493]

    Tincani E, Mannucci C, Casolari B et al.. “Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.” Haematologica (2006). PMID: 16757417 ↗

    L2TRIAL_NONRANDOMCited in: 13. Special Populations & Pregnancy
  494. [494]

    Bellesini M, Robert-Ebadi H, Combescure C et al.. “D-dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34161671 ↗

    L2SR_OBSCited in: 13. Special Populations & Pregnancy
  495. [495]

    Pelland-Marcotte MC, Bouchard V, Bégin E et al.. “Biomarkers in pediatric venous thromboembolism: a systematic review of the literature.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36958517 ↗

    L2SR_OBSCited in: 13. Special Populations & Pregnancy
  496. [496]

    Sharathkumar AA, Biss T, Kulkarni K et al.. “Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: A systematic review.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 31984669 ↗

    L2SR_OBSCited in: 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  497. [497]

    Sultan AA, West J, Tata LJ et al.. “Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study.” British journal of haematology (2011). PMID: 22145820 ↗

    L2COHORTCited in: 13. Special Populations & Pregnancy
  498. [498]

    Middeldorp S. “How I treat pregnancy-related venous thromboembolism.” Blood (2011). PMID: 21921048 ↗

    L5CASE_REPORTCited in: 13. Special Populations & Pregnancy
  499. [499]

    O'Brien SH, Zia A. “Hemostatic and thrombotic disorders in the pediatric patient.” Blood (2022). PMID: 34724564 ↗

    L5REVIEW_NARRATIVECited in: 13. Special Populations & Pregnancy
  500. [500]

    López-Jiménez L, Montero M, González-Fajardo JA et al.. “Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE).” Haematologica (2006). PMID: 16885044 ↗

    L2OTHERCited in: 13. Special Populations & Pregnancy
  501. [501]

    Borch KH, Hansen-Krone I, Braekkan SK et al.. “Physical activity and risk of venous thromboembolism. The Tromso study.” Haematologica (2010). PMID: 20801904 ↗

    L2OTHERCited in: 13. Special Populations & Pregnancy
  502. [502]

    Bakry HE, Abdellah MI, Khalaf HA et al.. “Efficacy and safety of direct oral anticoagulants in pediatric congenital and acquired heart disease: a systematic review and meta-analysis of randomized controlled trials.” Thrombosis journal (2026). PMID: 42032668 ↗

    L1SR_MA_RCTCited in: 13. Special Populations & Pregnancy
  503. [503]

    Parker K, Thachil J. “The use of direct oral anticoagulants in chronic kidney disease.” British journal of haematology (2018). PMID: 30183070 ↗

    L5REVIEW_NARRATIVECited in: 13. Special Populations & Pregnancy
  504. [504]

    Kitamura K, Colli E, Kikuyama R et al.. “Safety and Efficacy of a 24-Cycle Administration of a Drospirenone-Only Pill in Japanese Women.” The journal of obstetrics and gynaecology research (2026). PMID: 42152782 ↗

    L4TRIAL_NONRANDOMCited in: 13. Special Populations & Pregnancy
  505. [505]

    Tanaka Y, Taylor PC, Ritsema JAS et al.. “Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence.” Rheumatology and therapy (2026). PMID: 41903081 ↗

    L5TRIAL_NONRANDOMCited in: 13. Special Populations & Pregnancy
  506. [506]

    Hiratsuka D, Matsuo M, Ishizawa C et al.. “Increased risk of thromboembolism in adenomyosis: a case-control study.” Reproductive biomedicine online (2026). PMID: 42184779 ↗

    L3CASE_CONTROLCited in: 13. Special Populations & Pregnancy
  507. [507]

    Anderson DR, Dunbar M, Murnaghan J et al.. “Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.” The New England journal of medicine (2018). PMID: 29466159 ↗

    L1RCTCited in: 14. Prevention, Screening & Surveillance
  508. [508]

    Mahé I, Carrier M, Mayeur D et al.. “Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.” The New England journal of medicine (2025). PMID: 40162636 ↗

    L1TRIAL_NONRANDOMCited in: 14. Prevention, Screening & Surveillance
  509. [509]

    Weitz JI, Strony J, Ageno W et al.. “Milvexian for the Prevention of Venous Thromboembolism.” The New England journal of medicine (2021). PMID: 34780683 ↗

    L1TRIAL_NONRANDOMCited in: 14. Prevention, Screening & Surveillance
  510. [510]

    Eriksson BI, Dahl OE, Rosencher N et al.. “Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.” Lancet (London, England) (2007). PMID: 17869635 ↗

    L1RCTCited in: 14. Prevention, Screening & Surveillance
  511. [511]

    Cornell RF, Goldhaber SZ, Engelhardt BG et al.. “Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.” British journal of haematology (2020). PMID: 32314352 ↗

    L4TRIAL_NONRANDOMCited in: 14. Prevention, Screening & Surveillance
  512. [512]

    Yuan S, Titova OE, Zhang K et al.. “Plasma protein and venous thromboembolism: prospective cohort and mendelian randomisation analyses.” British journal of haematology (2023). PMID: 36734038 ↗

    L2SR_OBSCited in: 14. Prevention, Screening & Surveillance
  513. [513]

    Connors JM. “Testing and monitoring direct oral anticoagulants.” Blood (2018). PMID: 30201757 ↗

    L5REVIEW_NARRATIVECited in: 14. Prevention, Screening & Surveillance
  514. [514]

    Kakkar AK. “Prevention of venous thromboembolism in the cancer surgical patient.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19738112 ↗

    L5REVIEW_NARRATIVECited in: 14. Prevention, Screening & Surveillance
  515. [515]

    Levine MN. “New antithrombotic drugs: potential for use in oncology.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19738103 ↗

    L5REVIEW_NARRATIVECited in: 14. Prevention, Screening & Surveillance
  516. [516]

    Lauritsen J, Hansen MK, Bandak M et al.. “Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31821065 ↗

    L2OTHERCited in: 14. Prevention, Screening & Surveillance
  517. [517]

    Rana P, Levine MN. “Prevention of thrombosis in ambulatory patients with cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19752331 ↗

    L5REVIEW_NARRATIVECited in: 14. Prevention, Screening & Surveillance
  518. [518]

    Samama MM, Dahl OE, Mismetti P et al.. “An electronic tool for venous thromboembolism prevention in medical and surgical patients.” Haematologica (2006). PMID: 16434372 ↗

    L5OTHERCited in: 14. Prevention, Screening & Surveillance
  519. [519]

    Kristinsson SY, Pfeiffer RM, Björkholm M et al.. “Thrombosis is associated with inferior survival in multiple myeloma.” Haematologica (2012). PMID: 22511493 ↗

    L2OTHERCited in: 14. Prevention, Screening & Surveillance
  520. [520]

    Krauth MT, Lechner K, Neugebauer EA et al.. “The postoperative splenic/portal vein thrombosis after splenectomy and its prevention--an unresolved issue.” Haematologica (2008). PMID: 18556406 ↗

    L5OTHERCited in: 14. Prevention, Screening & Surveillance
  521. [521]

    Carroll BJ, Piazza G, Goldhaber SZ. “Sulodexide in venous disease.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 30394690 ↗

    L5REVIEW_NARRATIVECited in: 14. Prevention, Screening & Surveillance
  522. [522]

    Zhang L, Luo H, Gong Y et al.. “Antiplatelets match anticoagulants for VTE prevention after joint arthroplasty: a meta-analysis of randomized clinical trials.” EFORT open reviews (2026). PMID: 42383695 ↗

    L1SR_OBSCited in: 14. Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…